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ABSTRACT 
 
John Peyton Bohnsack: Epigenetic control of GABAA-R expression by ethanol 
(Under direction of A. Leslie Morrow) 
 Alcohol use disorders (AUDs) are a chronic debilitating psychiatric disease that account for one in 
ten preventable deaths and $223.5 billion dollars in lost economic costs in the United States alone.  
Despite the considerable social, psychological, and economic costs of AUDs, there exist few effective 
treatment options available.  One reason for this may be that the molecular underpinnings that drive 
alcohol dependence and the development of alcohol use disorders are still poorly understood.  A major 
component of the development of withdrawal and dependence symptoms is γ-aminobutyric acid A 
(GABAA) hypofunction that occur through the downregulation of GABAA receptors.  This work presents 
evidence showing that GABAA-R downregulation occurs through an epigenetic deacetylation mechanism 
that is mediated by histone deacetylase 2 and 3.  Importantly, this downregulation can be prevented by 
the administration of histone deacetylase inhibitors, genetic strategies targeting histone deacetylase 2 
and 3, and epigenetic strategies that target Gabra1 promoters using the CRISPR-Cas9 system.  The 
results presented herein demonstrate a novel mechanism for the development of alcohol dependence 
and other disorders where GABAA-Rs are dysregulated and may inform the development of new 
therapeutic strategies for the treatment thereof.   
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This thesis is dedicated to all those who have struggled with addiction.  
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CHAPTER 1: Introduction 
Alcohol Use Disorders – Background 
 Alcohol use disorders (AUDs) are chronic, debilitating, psychiatric diseases that have 
considerable societal, economic, and social consequences.  Currently, AUDs are the fourth leading 
preventable cause of death in the United States, with 88,000 people dying every year due to alcohol 
related causes1 and contributing $223.5 billion dollars in lost economic costs in the United States alone2.  
Despite this considerable socioeconomic burden, treatment options for AUDs are especially lacking, with 
just three treatment strategies that are FDA approved (disulfiram, naltrexone, and acamprosate).  Among 
the few individuals who seek treatment, relapse rates of 40-60%3 further compound the need to develop 
better therapeutic avenues for the treatment of AUDs.  One theoretical aspect that may contribute to both 
the high relapse rate and the few pharmacological treatment options is that underlying mechanisms that 
drive AUDs are still poorly understood even after many decades of research. 
In order to study the underlying mechanisms that drive addiction, it is necessary to establish a 
theoretical framework for which to understand the different facets of the disease.  AUDs are defined by 
the DSM V as meeting at least two of the eleven criteria that are outlined4.  While there are many different 
theories of addiction5, one prevailing theory suggests that addiction, including AUDs, can be defined as: 
chronically relapsing disorders, with a compulsion to drink alcohol, resulting in a loss of control in limiting 
alcohol consumption, culminating in a withdrawal state which is seen phenotypically in both rodent 
models of AUDs and human patients with AUDs as dysphoric like behavior (Figure 1B)6.  Continued 
cycles of preoccupation/occupation with alcohol, followed by an alcohol binge episode, resulting in a 
withdrawal causes a propensity for relapse driven by negative affect as opposed to positive reinforcement 
(Figure 1A)6-8.  
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Figure 1. Graphic representation of one theory of the development of alcohol use disorders.  A) 
There is a motivational switch between positive reinforcement and negative reinforcement as alcohol 
dependence progresses. B) Graphical representation a typical addiction cycle going through the three 
stages: preoccupation/anticipation, binge intoxication, and withdrawal. (Adapted from Koob 2013)6. 
  
Overall as an individual (or rodent) progresses through repeated addiction cycles, the motivation 
becomes more about removing the negative side-effects of repeated withdrawals.  Therefore, it is 
hypothesized that if one can remove the withdrawal side-effects or negative affect of the addiction cycle 
then one would be better able to treat the overall dependence disorder. Indeed, a phrase from ancient 
Ugarit, the “hair of the dog”9 suggests that even ancient humans knew that the easiest cure for the 
hangover was to get inebriated again. It should be noted that there are several other competing theories 
of addiction, notably that addiction is fundamentally habit formation and compulsions10,  and the theory 
described above represents one framework in which to develop therapeutic options for alcohol use 
disorders.  Alcohol use disorders are complex diseases and it is likely that any theoretical framework will 
not adequately account for all patients who suffer from the AUDs. This again describes the necessity to 
better understand the underlying mechanisms that contribute to AUDs.  
GABAA Receptors – Background 
GABAA-Rs are the major inhibitory neurotransmitter receptors in the adult brain of both rodents 
and humans11.  Binding of the endogenous ligand GABA causes a shift in receptor conformation that 
leads to an opening of a Cl- ion pore that allows Cl- ions to flow from the extracellular space into the 
intracellular space usually leading to a hyperpolarization of the membrane.  GABAA-Rs are usually found 
as pentamers, typically formed of 2 α subunits, 2 β subunits, and either a γ or δ subunit11.  There are 6 
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isoforms of the α subunit, 3 of the β subunit, 3 of the γ subunit, 3 of the ρ, and then 1 each of ε, θ, δ, and 
π11.  Different combinations of these subunits imbue distinct pharmacological and structural properties on 
the final assembled receptor as well as their subcellular localization. GABAA-Rs have long been 
implicated in both alcohol disorders12 and other disorders such as epilepsy, autism, and mood disorders13-
16.  Despite the clear importance of these receptors in regulating a number of homeostatic and 
pathological states, the understanding of GABAA-R regulation through structural studies and functional 
studies are still very lacking. A human GABAA-R has been crystalized but it consisted of a β3 
homopentamer and thus was not representative of most GABAA-Rs in nature17. However, several 
important breakthroughs have occurred.  The discovery that GABAA-Rs exist in separate populations, 
synaptic and extrasynaptic, has fueled a large body of work that has fundamentally changed the way 
neurotransmission is viewed.  
Extrasynaptic GABAA-Rs are located outside of the synapse and mediate a form of GABAergic 
inhibition called tonic current.  This occurs because the effective concentration of GABA required to 
activate these receptors is much lower, and these receptors tend to be in a persistently activated state18.  
GABAA-Rs containing the δ subunit are found exclusively extrasynaptically19, although not all 
extrasynaptic GABAA-Rs contain the δ subunit; indeed, the α5 subunit is often found in receptor 
complexes containing the γ2 subunit, and mediates tonic current in pyramidal neurons in the C1 and C3 
region of the hippocampus20.  The δ subunit lacks a gephyrin consensus site on the intracellular loop21, 
which explains why there is no synaptic localization of these receptors.  On the other hand, synaptic 
GABAA-Rs mediate a form of GABAergic inhibition called phasic inhibition.  This form of GABAergic 
transmission also regulates neuronal excitability, and generates network oscillations, such as the gamma 
frequency oscillation which is important for cognitive processing18.  These receptors tend to have a γ 
subunit present, which contains a gephyrin binding motif22,23.  Loss of the γ2 subunit results in decreased 
clustering of GABAA-Rs at the synapse and a high anxiety phenotype24 and mutations in this subunit have 
been known to contribute to genetic forms of epilepsy14.    
Other subunits besides δ and γ play an important role in the function and pharmacology of the 
final receptor complex.  The effects of the α subunit on receptor function are best illustrated by knockout 
and mutagenesis studies evaluating the effects of diazepam, which found that different α subunits are 
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responsible for different pharmacological and behavioral effects.  The α1 subunit is thought to mediate the 
sedative and anticonvulsive properties of diazepam25,26, the α2 subunit appears to mediate the anxiolytic 
effects27 and analgesic effects28, the α3 subunit appears to mediate the anti-absence effects29, while the 
α5 subunit appears to mediate the learning and memory effects30, and finally the α4 and α6 subunit are 
diazepam-insensitive31.  The α subunit also directly controls the EC50 for GABA, and is ranked: α6 < α1 < 
α2 < α4 < α5 < α3 when all other subunits are held constant32.  
Changes in GABAA-R expression or function are important as demonstrated by the number of 
pathological conditions in which  GABAA-Rs are dysregulated such as epilepsy14,33, schizophrenia34, 
depression35, insomnia36, autism15, Alzheimer’s disease37, and alcoholism12.  However, despite the 
implications in many of the most pressing neurological disorders of our time, little is known about how 
GABAA-Rs are regulated on a transcriptional level.  Indeed, few reports have described the intricate 
molecular mechanisms that describe how the activity of GABAA-Rs drive differences in expression, in 
stark contrast to molecular targets such as RAS or MYC that have been identified in cancer research.  
This makes it especially difficult when GABAA-Rs are implicated in one of the most pressing health 
problems of the current era, alcoholism. 
GABAA-Rs and Alcoholism 
 GABAA-Rs have long been known to be a target of ethanol38-40.  Acute ethanol potentiates the 
GABAA-R causing increased hyperpolarization of the cell (Figure 2)38-40.  Alcohol and homeostatic 
GABAA-R activation have many of the same physiological responses, including anxiolytic, sedative, 
anticonvulsant, hypnotic, cognitive impairment and motor incoordination effects12.  GABAA-Rs are fairly 
unique as they respond to concentrations of ethanol that are normally achieved after 1-2 standard drinks 
of ethanol (3-30mM), although it was only relatively recently determined that it was a specific type of 
GABAA-R that contain a δ subunit which were found to be the subtype responding to these 
concentrations41-44.   
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Figure 2. GABAA-R function after exposure to acute and chronic ethanol.  Under normal conditions 
GABA binds the receptor and Cl- enters the cell.  In the presence of acute ethanol, there is a potentiation 
of the GABAergic response, leading to increased hyperpolarization of the cell.  After chronic ethanol there 
is a diminished response to the binding of GABA and/or ethanol leading to GABAA-R hypofunction.   
Chronic ethanol exposure, unlike acute ethanol exposure, results in GABAA-R hypofunction45 and 
cross-tolerance to benzodiazepines46, suggesting that there is an adaptive GABAergic response to 
repeated ethanol exposures.  Early work demonstrated that there is a downregulation of the most 
abundant GABAA-R α1β2γ2 and upregulation of the α4βxγ2 receptor40,47-49. GABAA-R hypofunction is 
thought to contribute to many of the symptoms associated with alcohol withdrawal, including increased 
tremor, anxiety, insomnia, dysphoria, seizures, and cross-tolerance to benzodiazepines12.  It is suggested 
that the α1 subunit contributes heavily to these symptoms, as α1 knockout mice have an essential tremor, 
central nervous system hyperexcitability50 and increased seizure potential51.   Increased α4 expression is 
associated with increased anxiety52 and cross-tolerance to benzodiazepines49.   Therefore the decreased 
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expression of the α1 subunit and increased expression of the α4 subunit is likely to contribute too many of 
the withdrawal and dependence symptoms associated with alcohol use disorders.  Another line of 
evidence supporting this theory is that benzodiazepines are effective at treating many of the clinical 
symptoms associated with GABAA hypofunction. Since work in the 1960s, benzodiazepines have been 
used as the first line for the treatment of severe alcohol withdrawal53 in order to alleviate these symptoms 
and prevent mortality during alcohol withdrawal.  Unfortunately, benzodiazepines can be fatal when 
combined with alcohol, have high abuse potential, and build tolerance quickly making them unsuitable for 
long term treatment.  However, the possibility of treating GABAergic hypofunction as a means of 
intervention for alcohol use disorders seems viable, especially if this prevents some of the negative 
symptoms associated with ethanol withdrawal and therefore may diminish relapse potential. 
Mechanisms of GABAA hypofunction after chronic ethanol exposure 
 In order to identify suitable drug targets to prevent changes in GABAA-R subunit expression, first 
the molecular mechanisms that contribute to changes in subunit expression need to be understood.   The 
possibilities include changes in trafficking, transcription, translation, post-translational modifications, and 
degradation.  Each of these molecular processes are highly coordinated events that involved a multitude 
of different signaling cascades and at times, seemingly antagonistic pathways.  Despite this, extensive 
work has been done demonstrating that ethanol activation of PKCγ causes a decrease in α1 expression 
and an increase in α4 expression54-56 most likely through a trafficking mechanism57.  PKCγ activation has 
an inhibitory effect on GABAA mediated tonic currents58, which could explain the increased drinking  
phenotype and decreased behavioral sensitization to acute ethanol found in PKCγ knockout mice59, as 
decreased sensitivity to ethanol is associated with a higher drinking phenotype.  Furthermore, PKCγ 
knockout mice do not develop significant tolerance to ethanol60 suggesting that ethanol-induced 
adaptations in brain circuitry are not occurring.  Despite considerable evidence that PKCγ is a key player 
in the ethanol-induced adaptations in both GABAergic systems and other neural substrates of ethanol, 
PKCγ and other PKC isoforms remain poor targets for therapeutic development, as clinical trials (looking 
at cancer and diabetes endpoints) have demonstrated numerous adverse events and off-target effects, 
combined with poor therapeutic effects61.  Another problem is demonstrating that PKC inhibition is 
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working on the level of trafficking and that PKC inhibition induces long lasting effects that would be 
suitable for therapeutic development. 
 Chronic ethanol exposure also causes a change in GABAA-R gene expression62-67, suggesting 
that changes that occur on the protein level also occur on the transcript level.  Changes in gene 
transcription are likely to be upstream of changes in trafficking and therefore a therapeutic strategy that 
intervenes on the level of transcription may be more beneficial in the clinic.  The molecular players that 
drive changes in GABAA-R gene expression after chronic ethanol are still poorly understood.  Only one 
study has looked at the role of transcriptional factors regulating Gabra4 expression68.  In cultured cortical 
neurons, it was found that heat shock factor 1 regulates Gabra4 gene expression at physiologically 
relevant concentrations of ethanol (10-60 mM)68, although this study observed a decrease in Gabra4 
expression after ethanol.  There have been no studies that have specifically evaluated the role of 
transcriptional or other genetic factors in the regulation of the Gabra1 subunit by ethanol.  During 
homeostatic conditions it has been shown that Gabra1 is regulated by the neuron-specific specificity 
protein 469 and when cAMP response element-binding protein (CREB) is phosphorylated through a PKC 
or MAPK pathway70.  Additionally, it has been shown that miRNA181a causes a decrease in Gabra1 
expression71.  All of these proteins may potentially be involved in the regulation of Gabra1 after alcohol 
exposure. 
Epigenetics – Background 
 Epigenetics is an emerging field that studies changes in organisms that are due to modifications 
of gene expression rather than changes to the genetic code.  This usually occurs by post-translational 
modifications to either histones or DNA.  Several types of histone post-translational modifications (PTMs) 
have been identified including, acetylation, methylation, phosphorylation, sumoylation, and ubiquitination.  
Combinations of these PTMs work together to form the so-called “histone code” which contributes to 
regulation of gene transcription largely by remodeling chromatin structure.  Changes to certain histone 
modifications localized at specific gene and regulatory elements have been hypothesized to contribute to 
changes in gene transcription and regulation but there has not been a way to definitively test this 
hypothesis due to lack of robust gene-targeting technology. 
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Figure 3. Graphical representation of some of the most common modifications that can occur on 
histone tails.   Acetylation and methylation are by far the most studied of histone tail modifications.  
Different combinations of post-translational modifications leads to the histone code, which functions to 
control chromatin structure and regulate gene transcription. 
 
Acetylation 
Acetylation is one of the most well characterized histone post-translational modifications.  In 
general, acetylation leads to increased gene transcription usually by opening the chromatin, referred to as 
the euchromatin state.  Biochemically, this happens because acetylation removes the positive charge 
from the N-terminus of the histone protein, decreasing the affinity for the negatively charged phosphate 
groups of DNA to bind closely to the histone, allowing transcription factors and other regulators of gene 
transcription to bind to the DNA and initiate transcription72.  Acetylation of these residues can also lead to 
repair, replication, and condensation of the chromatin.   Histone acetylation and histone deacetylation is 
usually facilitated by large protein complexes containing one of two different classes of histone-modifying 
enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively.  
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Acetylation of lysines is usually recognized by a bromodomain, and these have been found in both the 
bromodomain proteins (BRD), which function as “readers” and recruit transcription factors, and repressor 
complexes.  Bromodomains are also found in some HATs such as EP300 and BCAF73. 
HATs transfer an acetyl group from acetyl-CoA to the lysine residue on the histone tail.  HATs are 
diverse in protein family, distribution, and the histone lysine residues they acetylate.  For example, HAT1 
is known to acetylate H4K5 and H4K12 while PCAF/GCN5 acetylates H3K9, H3K14, and H3K18.  Some 
HATs, such as CBP/P300 and TIP60 are known to acetylate many different lysines, while others like 
ScSAS2 and ScRTT109 have only been shown to only acetylate H4K16 and H3K56 respectively.  
Traditionally, the easiest classification structure has been between Type A HATs which contain a 
bromodomain, and Type B HATs which do not.  Type A HATs are traditionally located in the nucleus 
while Type B HATs are located in the cytoplasm74.  However, as more HATs have been discovered, such 
as CBP/P300, it has become apparent that traditional classification methods are not sufficient. 
Histone deacetylases remove an acetyl group from the lysine residue located on the histone tail.  
Unlike HATs, classification of the different HDACs is fairly simple and can be done by sequence 
homology and domain organization.  There are four classes of HDACs: class I which include HDAC1-3, 8 
which are primarily localized in the nucleus; class IIa which include HDAC 4,5,7,9 which are localized in 
both the nucleus and the cytoplasm; class IIb which include HDAC6 and HDAC10 that are mostly 
localized in the cytoplasm; class III, the sirtuins, which include Sirt1-7 and NAD+ dependent histone 
deacetylases and are localized in the nucleus (1, 2, 6, and 7), cytoplasm (1 and 2), and mitochondria (4 
and 5); and class IV which is HDAC11 and is found in both the nucleus and cytoplasm. HDACs can also 
be differentiated by pharmacology, as class I, II, and IV can be inhibited by trichostatin A (TSA) while the 
class III (sirtuins) are not.  Sirtuins are pharmacologically defined by being inhibited by nicotinamide. 
Class I, II and IV have zinc in the catalytic site.  Like HATs, HDACs are often found in large complexes 
with transcription factors and other chromatin remodeling proteins.  Several of these complexes are well 
characterized, including Sin3, nucleosome-remodeling HDAC (NuRD), and CoREST75. 
Methylation 
 In contrast to acetylation, which almost always increases or permits gene transcription, 
methylation on the lysine residues of histone tails has a more complex interaction with gene transcription.  
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Histone lysines can be either mono-, di-, or tri- methylated which contributes to the complexity of 
discerning what this modification does to gene transcription.  For example, H3K9me is usually activating, 
while H3K9me2 and H3K9me3 are thought to be canonical repressive marks.  Another level of complexity 
is added, as H3K9 methylation may be repressive when found in the promoter region of a gene, but 
permissive when found in the coding region.  Domains that recognize different methylated lysines include 
Chromo, Tudor, PHD, and MBT domains.  Histone methyltransferases methylate histone tails while 
histone demethyltransferases demethylate histone tails72,76.  
 Histone methyltransferases transfer a methyl group donated from S-adenosylmethionine to the 
lysine or arginine residues located on the histone tail.  There are three families that have been identified 
that catalyze this reaction, the SET-domain containing proteins, DOT1-like proteins, and arginine N-
methyltransferase.  Unlike acetyltransferases, methyltransferases are usually very specific and only 
modify only one single histone lysine residue.  It has been demonstrated, however, that certain members 
of this family will methylate other proteins besides histones76.  
 Demethylases are divided into the two families, the amine oxidases and the jumonji C, which 
contain the (JmjC)-domain and are iron-dependent dioxygenases.  Initially it was thought that methylation 
was a non-transient mark since no histone demethylase was discovered, however in 2004, LSD1, the first 
histone demethylase was discovered76. 
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Conclusions 
 
Figure 4.  Epigenetics is a quickly growing field but vastly understudied in addiction and 
neuroscience.  In order to determine # of publications, search criteria as defined in legend and was 
inputted into pubmed and # of hits was taken directly from the results page.  Results were not screened 
for primary or articles or review in order to more broadly encompass the academic literature for each 
given topic. 
 
Epigenetics continues to grow as a field as more information is discovered about different disease 
states that result from dysregulation of histone PTMs and as more pharmacological interventions 
targeting histones are developed to treat various disease states.  However, epigenetics are currently 
understudied in the neuroscience and addiction fields despite the growing body of work that suggests that 
epigenetic processes are very important both to the development and functioning of the organism.  
Addiction, in particular, seems well suited to involve epigenetic mechanisms, as there are known to be 
changes in gene transcription that underlie behavior and addictive behaviors.  Further, since neurons are 
post-mitotic, mutations are less likely to arise due to the lack of dividing cells, as is the case in cancer.  
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Finally, addiction involves an identified environmental source (drug of choice) that can influence 
epigenetic marks.  These factors suggest the need to better study epigenetic processes that occur during 
addiction. 
Epigenetic dysregulation in alcohol use disorders and models of alcohol dependence 
  Genetic studies looking for the genetic mechanism behind the development of AUDs have 
conclusively demonstrated that only about 30-70% of the risk to develop an AUD is due to genetic 
predisposition77, therefore other influences are due to environmental factors.  However, it is known that 
ethanol and other drugs of abuse cause stable changes to gene transcription that ultimately may 
contribute to the development of drug addiction78.  Since changes in chromatin structure regulate 
changes in gene transcription it seems likely that histone PTMs are probably modified in different states 
of addiction.  Indeed several seminal studies have demonstrated that there are drug-induced changes in 
chromatin structure via acetylation mechanisms.  For example, acute exposure to cocaine increases 
histone H4 acetylation with the immediate early genes c-fos and fosB79 while acute exposure to ethanol 
inhibited HDAC activity, increased H3Ac and H4Ac, increased NPY mRNA expression, and there was an 
increase in anxiolytic behavior as measured by elevated plus maze80.  On the other hand, chronic ethanol 
administration in a two bottle choice paradigm causes a decrease in H3 and H4 acetylation in the 
amygdala80 and the nucleus accumbens81.  However, other studies have found that chronic ethanol 
administration via intermittent vapor causes hyperacetylation in the prefrontal cortex and the amygdala82 
and the nucleus accumbens83, suggesting that route of ethanol administration is important for regulation 
of histone acetylation.  Corroborating these studies, treatment with a histone deacetylase inhibitor 
prevented anxiety-like behavior in the elevated plus maze80 and ethanol self-administration81,82.  This 
suggests that histone deacetylases are likely to be involved in remodeling chromatin structure after 
chronic ethanol consumption and that these changes have behavioral outputs. 
 There is an evolving role for HDACs in alcohol use disorders.  In humans, acute ethanol 
intoxication causes an increase in HDAC mRNA expression in the blood (all upregulated except HDAC9 
and HDAC10)84 while alcoholic postmortem hippocampus shows a decrease in HDAC2 expression85.  
Similar changes are observed in rodent models of alcohol use disorders and alcohol consumoption.  For 
example, studies in in the C57BL/6J mouse have shown that acute ethanol causes a decrease in Hdac2 
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and Hdac11 expression86.  Chronic alcohol consumption causes a decrease in HDAC2 expression in 
C57BL/6J mice in the hippocampus87 while another study found that chronic ethanol increased HDAC2 
expression in the ventral tegmental area88.  An inbred strain of rats bred for high drinking (P-rats) have 
intrinsically higher levels of HDAC2 than rats bred for low drinking (NP-rats).  P-rats have a high anxiety 
phenotype, both of which can be blocked by HDAC2 siRNA infusion into the CeA89 suggesting that 
HDAC2 is important for regulation of alcohol consumption and anxiety.  This suggests that targeting 
HDACs may be a viable strategy for the treatment of alcohol use disorders. 
The CRISPR-Cas9 System 
 The CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats) system has 
recently exploded as the premier methodology for gene editing due to the ability to make site specific cuts 
at almost any DNA loci90.  In nature, the CRISPR-Cas9 system acts as a bacterial immune system 
against bacteriophages by degrading sequences of viral DNA using a pair of RNAs, the tracrRNA, which 
activates the Cas9 system, and the crRNA which is complementary to the target dsDNA.  Cleavage of the 
site is determined by two elements, the complementarity between the base pairs of the target DNA and 
the crRNA, and the protospacer adjacent motif (PAM).  Most recent CRISPR-Cas9 systems have been 
engineered so that both the crRNA and the tracrRNA are in one expression system, called the short guide 
RNA (sgRNA)90,91. 
 
Figure 5.  Schematic demonstrating the regulatory elements required for the sgRNA and cleavage 
of DNA in the CRISPR-Cas9 system.  (Adapted from Jinek M. et al, 201291). 
 Mutating the CRISPR-Cas9 system so that it no longer has endonuclease activity makes it a 
powerful tool to deliver payloads to specific regions in the DNA.  Certain systems have been modified to 
include effector domains of different transcriptional factors or repressor domains92-94 that can be used to 
turn on or off endogenous genes or examine different regulatory elements.  This technology also allows 
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for epigenetic modulators to be attached to the Cas9 protein to make specific localized changes in the 
associated post-translational marks with different gene regions or regulatory elements93,94. 
Advances 
 It is clear that GABAA-Rs contribute significantly to alcohol withdrawal symptoms and 
dependence, especially since acute withdrawal symptoms are treated with positive allosteric modulators 
of the GABAA-R (benzodiazepines), or newer drugs that increase GABA release (acamprosate).  Thus, 
we reasoned that increasing GABAA-R function would be useful for the treatment of AUDs.  We decided 
to focus our attention on transcriptional regulation.  The reason for this was two-fold: first it is widely 
accepted that changes in transcription are usually what underlie changes in protein expression and 
therefore functional expression; and second that advances in understanding of changes of the genome 
through epigenetic mechanisms solve a long withstanding problem that attempts to explain differences 
between genetic predisposition and environmental influences.  Spurring this research was the publication 
from Mark Brodie’s lab at the University of Illinois at Chicago, which found that histone deacetylase 
inhibitors prevented GABAA receptor hypofunction in the ventral tegmental area (VTA).  We hypothesized 
based on the evidence that inhibiting histone deacetylases increased gene transcription that this was 
increasing transcriptional expression of GABAA-Rs, and this was what was ultimately restoring GABAA-R 
function in the VTA.  Thus, we decided to explore this mechanism in cerebral cortex using animal models 
established in our lab that implicate GABAA receptors in ethanol dependence pathology.  
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CHAPTER 2: Histone deacetylase inhibitors as a treatment for changes in GABAA-R expression 
after chronic ethanol 
Introduction 
 Chronic ethanol exposure has long been known to decrease expression of the GABAA α1 subunit.  
Downregulation of the α1 subunit have been experimentally linked to increased seizure 
susceptibility26,49,50, a clinically relevant symptom of those who suffer with AUDs.  This was demonstrated 
more conclusively with the use of α1 knockout animals since these animals presented with a constant 
tremor, phenocopying one of the most well known symptoms of chronic alcohol abuse, delirium 
tremens50.  They were shown to have compensatory changes in GABAA-R subunit expression that likely 
contributed to increased central nervous system hyperexcitability26.  These animals also had decreased 
zolpidem-induced loss of righting reflex (LORR), something that was seen after chronic ethanol 
exposure26.  Based on earlier research that showed that pharmaceutics that worked on an epigenetic 
level prevented changes in anxiety-like behavior in the open-field assay80, GABAA hypofunction88, and 
drinking81, we explored the hypothesis that histone deacetylase inhibitors prevented decreased 
transcription in the α1 subunit.  In order to test this hypothesis we needed to induce dependence in 
experimental animals, therefore we utilized a paradigm (intragastric gavage, i.g.) that had been previously 
been shown to produce symptoms of alcohol withdrawal and also allowed us to control the amount of 
alcohol given in order to better control both ethanol’s pharmacological effects and test the effects of 
ethanol dose  
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Methods 
 
Figure 6.  Schematic for chronic ethanol exposure and withdrawal with TSA administration. 
Schematic demonstrates strategy of 5g/kg intragastric ethanol gavage for 14 days followed by 24 hours of 
withdrawal.  TSA is administered on the last three days two hours before either gavage or sack. 
 
Animals and treatments.  Adult male Sprague Dawley rats (200-300g, 8-9 weeks old, Envigo) were 
used for in vivo studies.  Animals were housed in pairs with the same experimental condition in a 
temperature (23ºC) and humidity controlled vivarium under a 12h light/dark cycle (Lights on from 7:00 to 
19:00) and given ad libitum access to food and water.  For chronic ethanol administration and withdrawal 
experiments, rats were given a single water or ethanol dose (5g/kg, i.g.) once daily for 14d, then allowed 
to withdraw for 24h.  On the last two days of ethanol exposure and the day of withdrawal, rats were 
injected with either TSA (2mg/kg, i.p.) or vehicle (10% DMSO, 0.9% saline) 2h before gavage or sacrifice.  
 For acute ethanol gavage and withdrawal, animals were given a single water or ethanol dose 
(5g/kg, i.g.) then allowed to withdraw for 24h then sacrificed.  For acute gavage, animals were given a 
single H2O or ethanol dose (5g/kg, i.g.) then sacrificed after 1h. 
At the end of all experiments, rats were sacrificed by decapitation and cortices were dissected 
and snap frozen using dry ice.  Rats used for behavioral analysis (locomotor activity assay and zolpidem-
induced loss of righting assay) were not included in qPCR, western blot, or chromatin 
immunoprecipitation analysis.  All procedures were carried out in compliance with guidelines specified by 
the Institutional Animal Care and Use Committee at the University of North Carolina at Chapel Hill. 
 
Two bottle choice.  Adult male Wistar rats were used for two-bottle choice studies.  Animals were single 
housed in a humidity controlled vivarium under a 12h reverse light dark cycle (Lights on at 22:00 to 10:00) 
and given ad libitum access to food and water. On Monday, Wednesday, and Friday, animals were given 
a choice between either water (tap) and EtOH (20% v/v) for 24h; on non-drinking days, animals were 
given access to water only.  The side containing the EtOH was switched every drinking day to control for 
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side-dependent effects.  Animals developed a steady baseline of ethanol consumption after day 14.  On 
the 18th drinking session animals were given an injection of TSA or vehicle (2mg/kg, i.p.) two hours before 
bottles were placed on cages.   
 
 RNA isolation and qPCR.  Cortices were rinsed with ice-cold  then homogenized in Trizol (Ambion) and 
RNA was extracted and purified according to manufacturer’s instructions. RNA was quantified and quality 
controlled using a Nanodrop (all 260/280, and 230/260 values ≥ 1.8, Fisher Scientific).  Purified RNA (2 
µg) was reversed transcribed to a cDNA library using High Capacity RNA to DNA kit (Applied Biosystems) 
following manufacturer’s instructions.  DNA (10 ng per reaction) was then subjected to qPCR analysis 
using TaqMan gene expression probes and Taq Gene Expression MasterMix (Table 2, Applied 
Biosystems).  Reactions were run in duplicate on a StepOnePlus RT-PCR system (Applied Biosystems) 
using glyceraldehdyde-3-phosphate dehydrogenase (Gapdh) as a loading control95.  Data was analyzed 
using the ΔΔCT method and expressed as fold control.  
 
Subcellular fractionation.  Cortices were rinsed with ice-cold PBS then subjected to subcellular 
fractionation using the Subcellular Protein Fractionation Kit for Tissues (Thermo Scientific) following 
manufacturer’s instructions.  Protein concentrations in the resulting membrane or chromatin fractions 
were measured using the BCA method (Thermo Scientific).  
 
Western blot analysis.  Western blots were performed as previously described, with some 
modifications95.  Blots were blocked for 1h (room temperature) in Licor Blocking Buffer + PBS (1:1 
v/v).  Primary antibodies (Table 1) were added to the blot in Licor + PBST (1:1 v/v, 0.1% Tween 20) and 
incubated overnight at 4ºC.  Blots were washed 3× with PBST, then incubated for 1h (room temperature) 
with 2º antibodies conjugated to a fluorophore.  Blots were then washed 3× with PBST, then 1× with PBS 
to remove excess Tween 20.  Bands were visualized using the Odyssey Classic Imaging System 
(Licor).  Results were normalized to β-actin, GAPDH, or histone 3 depending on the cellular fraction and 
condition to account for discrepancies in loading.  Loading controls were also evaluated for changes in 
expression.  Loading control normalized values were then expressed as percent control values.   
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Locomotor activity assay.  General locomotor activity was assessed on day 14 of administration (light 
cycle, 14:00), 24h into withdrawal and 2h after TSA/vehicle injections by placing rats in Plexiglas open-
field chambers (43.2 cm × 43.2 cm; Med Associates).  A second session was done after ethanol exposure 
(5g/kg, i.g.) approximately 4h after the previous session. Horizontal distance traveled (cm) was 
determined from the number of photobeam breaks in 2 minute time intervals using Activity Monitor 
software (Med Associates) for a total of 30 minutes.  Time spent in the center (21.6 × 21.6 cm) of the 
open field was expressed as a % of total locomotor activity time.  This ratio was chosen to account for 
differences in total locomotor activity between treatment groups.  Groups were counterbalanced to 
different chambers.  Heat maps of locomotor activity were created using QGIS Desktop software (QGIS 
Development Team).  
 
Zolpidem-induced LORR.  Zolpidem-induced hypnosis was assessed 24h after the final ethanol gavage 
on day 14 and 2h after TSA injections (light cycle, 14:00).  Rats were administered zolpidem (60 mg/kg 
i.p., dissolved in vehicle (40% (w/v) β-cyclodextrin in 0.9% saline); Tocris) and placed in the supine 
position in custom-built trellises26. Duration of LORR was defined as the time required to regain the ability 
to right three consecutive times within one minute.  
 
Statistics.  All groups were randomly assigned.  GraphPad Software was used for statistical analysis.  
Two-way ANOVAs were performed to determine significance for all experiments that contained more than 
two groups.  Bonferroni’s post-hoc test was used to perform multiple comparisons between groups in 
order to determine significance.  Student’s unpaired two-tailed t-test was used to compare two groups.  
Values were excluded from study (decided a-priori) if they were two significant deviations from the 
mean.  Values were excluded post-hoc if they failed any quality control checks (e.g. amplification failure, 
sample processing errors (qPCR), ineffective knockdown or expression).  Significance was set at p < 
0.05. 
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Results 
 Previous studies have shown that after 14d of liquid diet that there is a downregulation of the 
GABAA-R α1 subunit and that this correlates to many of the behavioral phenotypes observed with alcohol 
use disorders such as increased anxiety, insomnia, dysphoria, and increased seizure susceptibility.  
Since we were interested in whether histone deacetylase inhibitors would prevent decreased expression 
of the Gabra1 transcript we used a chronic ethanol gavage followed 24h of withdrawal with three days of 
daily TSA injections (2mg/kg, i.p.), changes in Gabra1 expression were determined using quantitative 
polymerase chain reactions (qPCR).  Chronic gavage causes blood alcohol content (BACs) of 208.3±13.9 
mg/dL which is similar to the 250 mg/dL BACs observed in human patients at time of admittance to the 
emergency room96. 
 
 
Figure 7.  TSA administration prevents changes caused by chronic ethanol exposure and 
withdrawal. Fourteen day of gavage followed by 24h withdrawal caused a downregulation of the Gabra1 
transcript in the cortex, and an upregulation of the Gabra4 transcript.  Administration of TSA on the last 
three days of the experiment prevented the downregulation of Gabra1 and the upregulation of Gabra4.  
No effect of either ethanol or TSA treatment was noticed on any of the other subunits tested: Gabrg2, 
Gabrd, Gabrb2, and Gabrb3.  n = 5-6.  **** = p < 0.0001.  Significance was determined using two-way 
ANOVAs followed by Bonferroni corrections.  All data are plotted as mean ± S.E.M.   
 
In agreement with previous studies using a liquid diet drinking paradigm62, 14d chronic ethanol (5g/kg, i.g. 
daily) administration caused a decrease in Gabra1 transcript (Figure 7, 0.35 ± 0.07 fold control). Further, 
TSA (2mg/kg, i.p.) prevented the effect of ethanol (Figure 7, Gabra1: 0.99 ± 0.10 fold control p < 0.0001).  
We also observed an increase in Gabra4 transcript (Figure 7, 2.14 ± 13 fold control), in accordance with 
previous studies, that was also prevented by the administration of TSA (Figure 7, Gabra4: 0.93 ± 0.08 
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fold control, p < 0.0001).  A significant interaction ethanol × TSA was observed for both Gabra1 (F1,20 = 
19.42, p = 0.0003, n = 6) and Gabra4 (F1,20 = 30.11, p < 0.0001, n = 6).  We did not observe any 
significant changes on transcript level on Gabrg2, Gabrd, Gabrb2, and Gabrb3 in any of the three 
experimental groups, also in accordance with previous observations that chronic ethanol exposure in the 
cortex selectively changes expression of Gabra1 and Gabra4.  Since we observed specific changes in 
transcript levels we next wanted to determine if there were changes in protein, which is more 
representative of a functional receptor, but also because we wanted to know if the effects we observed 
were merely on a transcriptional level. 
	
Figure 8.  TSA prevents chronic ethanol-induced changes in membrane expression of the GABAA-
R α1 and α4 subunit.  Chronic exposure (14d) and 24hr withdrawal cause a decrease in the expression 
of the α1 subunit and an increase in α4 expression.  This is prevented by the administration of TSA.  
There were no observed changes in expression of the γ2, δ, β2, and β3 subunits.  n = 5-6.  * = p < 0.05, 
*** = p < 0.001.  Significance was determined using two-way ANOVAs followed by Bonferroni corrections.  
All data are plotted as mean ± S.E.M.   
 
 In accordance with the results from our qPCR data, there was a decrease in α1 membrane 
expression (Figure 8, 67.37 ± 2.46% control) that was prevented by the administration of TSA (Figure 8, 
88.83 ± 2.30% control, p < 0.05).  We also observed an increase in α4 membrane expression (Figure 8, 
129.70 ± 3.45% control) that was also prevented by the administration of TSA (Figure 8, 96.48 ± 7.44% 
control, p < 0.01).  A significant interaction between ethanol and TSA exposure for α1 subunit expression 
was found (F1,19 = 10.53, p = 0.0043, n = 6,6,6,5) using two-way ANOVA.  A significant main effect of TSA 
exposure on α4 subunit expression (F1,18 = 10.09, p = 0.0052, n = 6,5,5,6) was found using two-way 
ANOVA.  Similar to what we found on a transcript level, membrane expression of the GABAA-R subunits 
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γ2, δ, β2, and β3 did not change after any experimental manipulation.  We wanted to further validate 
these findings by looking at a functional measure of the α1 subtype of GABAA receptors. 
 The nonbenzodiazepine hypnotic zolpidem is a selective positive allosteric modulator of the α1 
subunit.  Thus, we hypothesized that animals would have decreased pharmaco-behavioral responses 
after chronic ethanol if there were indeed functional changes in the number of α1 containing GABAA-Rs.  
The lab has previously shown this to be true in α1 knockout mice26 as α1 knockout mice have shorter 
LORR.  The α4 subunit is not thought to be modulated by zolpidem.  After chronic ethanol exposure and 
withdrawal, rats were given a 60 mg/kg (i.p.) injection of zolpidem and placed supine.  The time elapsed 
to righting three times in one minute was the criteria for reinstatement of righting reflex. 
 
 
Figure 9.  TSA prevents decrease in zolpidem induced LORR.  A) Picture of rats engaged in assay for 
LORR.  B) Chronic ethanol causes a decrease in zolpidem-induced LORR that is prevented by the 
administration of TSA. n = 7-8.  * = p < 0.05, ** = p < 0.001.  Significance was determined using two-way 
ANOVAs followed by Bonferroni corrections.  All data are plotted as mean ± S.E.M.  
 
We found that 14d ethanol exposure and 24h withdrawal caused a 52 ± 6.3% decrease in the 
duration of the zolpidem-induced LORR that was prevented by the administration of TSA (89.64 ± 9.11% 
control.  A significant interaction between ethanol and TSA exposure (F1,25 = 6.740, p = 0.0156, n = 
8,7,7,7) was found using two-way ANOVA.  This suggested that our chronic ethanol paradigm caused a 
decrease in the functional α1 receptors and that this could be prevented by the administration of TSA. 
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 Since chronic ethanol exposure can also cause anxiety in both humans and animal models, we 
wanted to determine if TSA administration would also prevent an anxiety-like phenotype.  We used open-
field assays to measure both center-time (a measure of anxiety-like behavior) and locomotor activity.  
 
 
Figure 10.  TSA administration prevents changes induced in open-field behavior caused by 
chronic ethanol.  A) Representative heatmaps showing locomotor activity after different experiments.  B) 
TSA administration prevents changes in center time caused by chronic ethanol and withdrawal.  C) TSA 
administration prevents changes in total distance traveled caused by chronic ethanol and withdrawal.  * = 
p < 0.05, ** = p < 0.01, **** = p < 0.0001.  n = 9-10.  Significance was determined using two-way ANOVAs 
followed by Bonferroni corrections.  All data are plotted as mean ± S.E.M. 
 
 In accordance with other reports that have shown that TSA administration prevents anxiety-like 
behavior80, our open-field results suggested that chronic ethanol gavage causes an open-field phenotype 
and that this can be prevented by the administration of TSA (Figure 10).  Ethanol administration for 13 
days with 24h withdrawal produced decreases in both center time expressed as a percent of total 
locomotion (Figure 10B, K, 0.98 ± 0.14%) and total locomotor activity (Figure 10C, 1979 ± 166cm), and 
was prevented by the administration of TSA (Figure 10B, K, 3.00 ± 0.73%, p < 0.05; Figure 10C, 2762 ± 
246cm, p < 0.01).  A significant interaction was found between ethanol and TSA exposure (F1,34 = 12.41, 
p = 0.0012, n = 10,9,9,10) using two-way ANOVA for center time.  A significant interaction was found 
between ethanol and TSA exposure (F1,34 = 11.05, p = 0.0021, n = 10,9,9,10) using two-way ANOVA for 
total locomotor activity.  TSA had no effects on baseline locomotor activity or center time, consistent with 
previous studies. 
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Figure 11.  TSA administration decreases EtOH consumption in a two-bottle choice chronic 
intermittent ethanol paradigm.  A) Schematic for CIE and TSA injection schedule.  B) A single TSA 
injection (2mg/kg, i.p.) prevents EtOH consumption over 24h time period.  C) TSA injections plus EtOH 
does not change the volume of H2O that is consumed.  D) There is a trend towards a decrease in EtOH 
preference after TSA injections.  n = 4.  * = p < 0.05, n.s. = not significant.  Significance was determined 
using Student’s unpaired two-tailed t-test (B, C) or one-way ANOVA with Bonferroni post-hoc tests.  All 
data are plotted as mean ± S.E.M. 
 
 It has been previously reported that HDAC inhibitors decrease ethanol preference and ethanol 
drinking80-82 in animals.  We verified that in our hands TSA injections given 2h before access to ethanol 
caused a decrease in ethanol consumption.  TSA injections caused a significant decrease in the amount 
of ethanol consumed (1.6±0.7 g/kg/24h) compared to vehicle treated controls (3.7±0.4 g/kg/24h) when 
analyzed with a Student’s unpaired two-tailed t-test (t6 = 2.632, p = 0.039).  There was no difference in 
H2O consumed between TSA treated (56.8±13.0 mL) or vehicle treated animals with access to ethanol 
(41.0±15.0 mL) or without it (38.5±3.6 mL).  There was also a decrease in ethanol preference after TSA 
injections (0.1±0.1 EtOH preference ratio) compared to vehicle injections (0.24±0.05 EtOH preference 
ratio) but this trend was not significant (t6 = 1.776, p = 0.1261).   
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 Convinced that TSA could prevent changes in α1 expression and α4 expression after chronic 
ethanol and withdrawal and could prevent changes in open-field behavior, and related behavioral 
pharmacology (Zolpidem LORR), we next wanted to determine if changes occurred in GABAA-R 
expression after intoxication or withdrawal, or if this was truly a dependence mechanism. 
 Previously it was shown in the hippocampus that acute ethanol exposure and withdrawal induces 
rapid changes in GABAA-R expression49.  We wanted to see if a single withdrawal episode after a single 
intoxicating dose (5g/kg) would also induce changes in GABAA-R expression in the cortex (Figure 12). 
 
Figure 12.  Schematic of acute ethanol exposure and withdrawal. Naïve rats were given one 
intoxicating dose of ethanol (5g/kg) via oral gavage, then returned to home cage for 24hrs, after which 
they were sacrificed by decapitation and cortices were acquired for biochemical and molecular analysis. 
 
 
Figure 13.  Acute ethanol exposure and withdrawal does not alter GABAA subunit expression.  n = 
6. Significance was determined using Student’s unpaired two-tail t-test.  All data are plotted as mean ± 
S.E.M. 
 
 We first analyzed changes in transcript using qPCR after acute ethanol and withdrawal and found 
that there were no changes in any transcript levels measured. 
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Figure 14.  Acute ethanol exposure and withdrawal does not alter membrane expression of 
GABAA-R subunits.  A) Representative blots of GABAA-R subunits in membrane fraction after acute 
ethanol exposure and withdrawal.  B)  Quantification of GABAA-R expression after acute ethanol 
exposure and withdrawal.  n = 5-6.  Significance was determined using Student’s unpaired two-tail t-test.  
All data are plotted as mean ± S.E.M. 
 
 Similar to the results observed in transcript, acute ethanol exposure and withdrawal did not 
induce any changes in GABAA-R subunit expression of the subunits measured (Figure 14). 
 We next wanted to evaluate if there were any changes in GABAA-R subunit expression after an 
acute ethanol exposure to see if ethanol had any pharmacological effects on GABAA-R subunit 
expression.   
 
Figure 15.  Schematic of acute intoxication. 5g/kg was given via oral gavage to naïve rats, then after 1hr 
animals were sacrificed and cortices collected for biochemical and molecular analysis. 
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Figure 16.  Acute intoxication does not changes GABAA-R subunit transcript expression. n = 6.  
Significance was determined using Student’s two-tailed unpaired t-test.  All data are plotted as mean ± 
S.E.M. 
  
Acute intoxication (5g/kg) for 1h did not produce any significant changes in any GABAA-R subunit 
transcript that was measured. 
 
 
Figure 17.  Acute ethanol intoxication does not alter membrane expression of GABAA-R subunits.  A) 
Representative western blots showing that acute ethanol exposure does not change GABAA-R subunit expression.  
B) Quantification of western blot data showing that there is no significant changes in GABAA-R subunit expression of 
those measured.  n = 9.  Significance was determined using Student’s two-tailed unpaired t-test.  All data are plotted 
as mean ± S.E.M. 
 
 In accordance with qPCR data, acute intoxication also did not change membrane expression of 
any of the GABAA-R subunits measured. 
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 We next evaluated acute ethanol effects on locomotor activity in rats that had been chronically 
treated with ethanol (13 days) to see if there were any adaptations to ethanol locomotor activity after 
chronic ethanol. 
 
Figure 18.  Acute ethanol exposure in chronic ethanol exposed rats increases time in center.  A) 
Acute ethanol exposure increases percent center time in chronic ethanol exposed rats.  B) There are no 
significant changes in locomotor activity in chronic exposed rats.  n = 9-10.  * = p < 0.05. Significance was 
determined usingtwo-way ANOVA followed by Bonferroni post-hoc tests.  All data are plotted as mean ± 
S.E.M. 
 
 In chronic ethanol exposed rats (13 days), acute ethanol gavage (5g/kg) followed by immediate 
open-field assessment increased percent time in center.  Two way ANOVA revealed a significant effect of 
ethanol (F1,34 = 7.337, p = 0.0104, n = 10,9,9,10) but did not reveal a significant interaction between 
ethanol and TSA nor did multiple comparison tests reveal a significant effect of administration of TSA to 
chronic ethanol exposed animals.  Acute ethanol gavage did not produce any changes in total locomotor 
activity.  
 Finally, we next tested to see if chronic ethanol-induced changes in Gabra1 expression could be 
prevented by the administration of TSA in a discrete brain region.  The PFC is known to be involved in 
both humans and rodents in alcohol dependence97,98.  In order to test this hypothesis we used our 
standard 15 day chronic ethanol exposure and TSA treatment paradigm (Figure 6) followed by PFC 
microdissection then analyzed GABAA-R subunit expression using qPCR. 
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Figure 19.  TSA prevents effects of chronic ethanol on Gabra1 expression in the PFC.  
Microdissected PFC from chronic ethanol-exposed and TSA animals revealed that changes in Gabra1 
expression induced in whole cortex are applicable to the PFC, but changes in Gabra4 expression are not.  
n = 6.  ** = p < 0.01, *** = p < 0.001.  Significance was determined using two-way ANOVA followed by 
Bonferroni posthoc test.  All data are plotted as mean ± S.E.M. 
 
Chronic ethanol exposure caused a decrease in Gabra1 expression in the PFC (0.47 ± 0.05 fold 
control) that was prevented by the administration of TSA (0.87 ± 0.06 fold control).  Unlike what was 
observed in whole cortex (Figure 7), there was no change observed in Gabra4 expression after chronic 
ethanol (0.97 ± 0.19 fold control) or TSA exposure (0.87 ± 0.05 fold control).  There was a significant 
interaction between TSA and EtOH exposure on Gabra1 expression (F1,20 = 12.67, p = 0.0020, n = 
6,6,6,6) observed by two-way ANOVA.  There was no effect of EtOH and/or TSA exposure on Gabrg2 or 
Gabrd expression. 
 
Conclusion 
 Chronic ethanol exposure via gavage causes a decrease in Gabra1 and α1 expression and an 
increase in Gabra4 and α4 expression similar to what has been observed in other ethanol exposure 
paradigms47,62 and brain regions49.  These effects were prevented by the administration of TSA, implying 
that inhibiting HDACs can prevent changes in GABAA-R subunit expression caused by chronic ethanol.  
Further, these effects may be relevant functionally, as treatment with TSA prevented the decrease in 
zolpidem-induced LORR caused by chronic ethanol exposure.  Treatment with TSA also prevented 
dependence-related behavior, as it prevented decreases in center-time and locomotor effects in open-
field locomotor assays, suggesting that TSA administration can prevent open-field phenotype induced by 
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chronic ethanol exposure.  One confounding variable is that open-field test can be used to measure 
anxiety, but in our case we observed decreases in locomotor activity as well as decreases in center time 
which confounds the anxiety-like behavior that could be measured by open-field. Nonetheless, since TSA 
prevented decreases in open-field like phenotype, these results confirm and extend other studies that 
have also shown that histone deacetylase inhibition prevents the effects of chronic ethanol in the EPM, a 
behavioral task used to evaluate anxiety and changes in behavior during ethanol-withdrawal80,99.  These 
changes appear to be dependent on chronic ethanol exposure and withdrawal as neither a single acute 
intoxicating dose nor a single withdrawal episode produced any changes in GABAA-R subunit expression 
measured with qPCR or WB.  Furthermore, TSA appeared to trend towards preventing anxiolytic effects 
of acute ethanol dose in alcohol dependent rats but these effects were not significant similar to what other 
groups have found in the EPM100.  TSA administration appears to have opposite effects on drinking 
behavior depending on the paradigm used to induce drinking dependence, for example, one group using 
chronic intermittent ethanol (CIE) two-bottle choice found that histone deacetylase inhibitors (TSA, SAHA, 
MS275) decrease drinking in mice, and SAHA decreases operant responding in rats81 while another 
group found that rodents drinking after dependence induced by chronic intermittent vapor exhibited an 
increase in the amount of alcohol they consumed101.  Another group found that TSA administration 
decreased drinking in a two-bottle choice paradigm in alcohol-preferring P-rats but not alcohol non-
preferring rats NP-rats101, suggesting that genetic factors may also play a role in TSA effectiveness, 
similar to the suggestion that 50% of risk of alcohol dependence is due to genetics.  
 The changes observed were in whole cortex lysates, which suggest a broad mechanism for 
histone deacetylase inhibition prevention of chronic ethanol exposure.  However, these changes are only 
somewhat applicable to changes in more discrete brain regions, such as PFC, where only Gabra1 
expression and not Gabra4 expression was modified by chronic ethanol.  Nonetheless, TSA 
administration prevented the decrease of Gabra1 expression providing further evidence to the growing 
body of work80-82,99 showing the utility of HDAC inhibition as a potential therapeutic strategy for the 
treatment of AUDs. 
 Future studies will need to be conducted in order to evaluate if changes in expression are 
coupled with changes in functional activity.  Other studies will be needed to determine if there is cortical 
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region specificity to these changes, cell-type specific changes, and what are the molecular players that 
drive these changes.  Currently, the necessary transgenic rat lines to gain genetic access to the cell-type 
and molecular players are being developed and may be available soon to help answer these questions.   
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CHAPTER 3: Role of histone deacetylases in chronic ethanol exposure  
Introduction 
 There is a growing role for histone deacetylases in AUDs and alcohol dependence.  Human 
studies have recently identified that acute ethanol challenge causes changes in histone deacetylase 
expression84.  Postmortem studies identified that there were changes HDAC2 expression in the 
hippocampus in patients with AUDs85.  Meanwhile, animal studies have shown that HDAC expression 
changes after acute84, chronic88, adolescent99, or in inbred alcohol preferring rats101 suggesting that 
HDACs may play a critical molecular player in the development and maintenance of AUDs.   
 In general, histone deacetylases work by de-acetylating lysine residues on histone tails, which 
leads to condensation of the chromatin.  Thus, we hypothesized that ethanol increased HDAC activity and 
that this lead to a decrease in Gabra1 expression.   
 
 
Figure 20.  General hypothesis that HDAC activation leads to ethanol-induced changes in Gabra1 
expression.  
 
 Previous studies have shown that cocaine alters GABAergic function and expression in the 
nucleus accumbens and that this can be prevented by the administration of the HDAC inhibitor MS-
275102.  Another study found that chronic ethanol injections (i.p.) followed by HDAC inhibition (either TSA 
or SAHA) prevent changes in GABAA hypofunction in the VTA88.  These results may be due to changes in 
HDAC2 as HDAC2 is known to regulate synaptic GABAA-Rs, as knockdown of HDAC2 decreased mIPSC 
amplitude in the hippocampus, with a decrease in the γ2 expression, while overexpression of HDAC2 
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caused an increase of α2 expression in CA1 pyramidal neurons103.  This study also showed that HDAC2 
suppresses excitatory transmission in CA1 pyramidal neurons which is counter to another study that 
showed HDAC2 knockout mice have increased excitatory post-synaptic potentials and HDAC2 
overexpression mice have decreased excitatory post-synaptic potentials in the CA1 region of the 
hippocampus104.  The role of HDAC inhibition on GABAA-R expression appears to be brain region 
specific.  Several questions therefore existed: first, does ethanol change expression of HDACs in cortex; 
second, do HDACs interact directly with regulatory regions of GABAA-R genes in the cortex; and finally do 
HDAC inhibitors work by preventing changes in HDAC expression or association with the GABAA-R 
promoters. 
 
Methods 
Chromatin immunoprecipitation.  Cortices were rinsed with ice-cold PBS, minced into approximately 1-
3mm pieces and then cross-linked in 1% formaldehyde (Thermo Scientific) by rotation for 10 minutes at 
room temperature.  The cross-linking reaction was quenched using 125 mM glycine for 5 minutes at room 
temperature.  Samples were centrifuged at 1,600×g for 5 minutes at 4ºC then washed with ice-cold PBS 
and spun again at 1,600×g for 5 minutes at 4ºC.  Samples were lysed using ChIP lysis buffer (10 mM 
Tris-HCl pH 8.0, 10 mM NaCl, 0.2% v/v NP-40, and 1 mM phenylmethylsulfonyl fluoride) on ice for 30 
minutes, then homogenized and spun down at 2,400×g for 10 minutes at 4ºC. Nuclei were lysed in 
nuclear lysis buffer (10 mM Tris-HCl, ph 8.0, 50 mM EDTA, 1%(v/v) SDS, and protease inhibitors) on ice 
for 10 minutes then sonicated to shear chromatin.  Chromatin shearing of less than 500 bp was verified 
by running aliquots on 2% agarose gels.  Following sonication, chromatin samples were spun for 
18,000×g for 10 minutes at 4ºC and DNA concentrations were determined using a Nanodrop (Fisher 
Scientific).  Equal amounts of chromatin were incubated overnight at 4ºC with antibody (Table 1), and an 
aliquot was set aside for input to ensure equal loading.  PureProteome™ Protein G Magnetic Beads 
(Millipore) were added to chromatin samples for 1hr at 4ºC, then complexes were washed, eluted in 1% 
(w/v) SDS, 0.75% (w/v) sodium bicarbonate buffer, and crosslinks were reversed overnight at 65ºC.  DNA 
was purified using QIAquick PCR Purification Kit (Qiagen) and analyzed using SYBR® Green Real-Time 
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PCR Master Mixes (Thermo Scientific) following manufacturer’s instructions.  Primers for qPCR analysis 
are included in Table 2. 
 
Primary cultured cortical neurons.  Cerebral cortices from Sprague Dawley rat pups (pn = 0) were 
isolated, minced finely (~1mm3), digested with 10 units of papain and ~1mg cysteine for 30 minutes at 
37°C. Neurons were dissociated by titrations using a 10 mL serological pipette.  Neuron density was 
determined using trypan blue (1/10 dilution) and counted manually using a hemocytometer.  Neurons 
were seeded at 1,000,000 neurons per well (6 well) or 100,000 neurons per well (12 well) on poly-D-
lysine coated plates  and grown for 18 days in vitro at 37ºC and 5% CO295. Cells were fed every three 
days by removing one third of the media and replacing it with fresh media (DMEM + B27 + penicillin and 
streptomycin).  Antibiotics were removed on DIV14 as these are known to interfere with GABAA-R 
functional responses.  
 
In vitro drug exposure.  After DIV18, trichostatin A, (TSA, 500 nM, Tocris), suberoylanilide hydroxamic 
acid, (SAHA, 3 μM, Tocris), (2E)-N-(2-amino-4-fluorophenyl)-3-[1-(3-phenyl-2-propen-1-yl)-1H-pyrazol-4-
yl]-2-propenamide (RGPF966, 24 nM, 80 nM, Cayman Chemical), (2E)-3-[5-[(1E)-3-(3-fluorophenyl)-3-
oxo-1-propen-1-yl]-1-methyl-1H-pyrrol-2-yl]-N-hydroxy-2-propenamide (MC1568, 1 μM, Cayman 
Chemical), or sodium butyrate (1 mM, Tocris) or equivalent volume vehicle (100% v/v DMSO) was added 
directly to cell culture media for 4hr or 7d.  Ethanol (50 mM) was co-exposed with drugs (or vehicle) for 
4hr. Experiments were stopped by placing cell-culture plates on ice, cells were then washed twice with 
DPBS, and then lysed in either Trizol or 0.32M sucrose homogenization buffer.  Subcellular fractionation 
was performed on certain samples in order to obtain rough membrane fractions and nuclear fractions. 
 
Subcellular fractionation. 
Membrane (P2 fraction).  Cells were lysed in PBS containing 0.32M D-sucrose then spun at 1,000×g for 
10 minutes at 4°C.  The supernatant was then spun for 12,000×g for 30 minutes at 4°C, pellets were then 
washed once with PBS and spun again for 30 minutes at 12,000×g at 4°C.  Supernatant was discarded 
and pellets were resuspended in RIPA buffer (25mM tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium 
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deoxycholate, 1% Triton X100) containing protease and phosphatase inhibitors (Halt, Thermo Scientific).  
Protein concentration was measured using the BCA assay. 
 
Nuclear fraction.  Cells were resuspended in cell lysis buffer (10mM HEPES, 1.5mM MgCl2, 10mM KCl, 
pH 7.4).  Cells were lysed by passing through a 27 gauge needle 10 times, then left on ice for 20 min.  
Nuclei were pelleted by centrifugation at 720×g for 5 min at 4°C. Cells were washed once with lysis 
buffer, then passed through a 25 gauge needle 10 times, nuclei were again pelleted by centrifugation at 
720×g for 5 min at 4°C.  Supernatant was discarded and pellets were resuspended in RIPA buffer (25mM 
Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X100) containing protease and 
phosphatase inhibitors (Halt, Thermo Scientific).  Protein concentration was measured using the BCA 
assay. 
 
Lentiviral shRNA knockdown.  Lentiviral experiments for HDAC1 knockdown experiments used shRNA 
from the RNAi Consortium library, provided by the UNC Lentiviral core.   
Target sequences for HDAC1 shRNAs were as follows: 
5’ GCTTGGGTAATAGCAGCCATT 3’ 
5’ CCGGTATTTGATGGCTTGTTT 3’ 
5’ CCCTACAATGACTACTTTGAA 3’ 
5’ GCCAGTCATGTCCAAAGTAAT 3’ 
5’ GCGTTCTATTCGCCCAGATAA 3’ 
Lentivirus shRNA experiments for HDAC2 used shRNA plasmids from Origene (Cat# TL7118660).  
Target sequences for HDAC2 shRNAs were as follows: 
5’ AGAAAGTGTGCTACTATTATGACGGTGAT 3’,  
5’ GCTTGTGATGAAGAGTTCTCAGATTCTGA 3’,  
5’ ACAACAGATCGCGTGATGACCGTCTCATT 3’,  
5’ TCAAAGGTCACGCTAAATGTGTAGAAGTA 3’.  
Control experiments used a virus containing a scrambled DNA (SHC002, Sigma Aldrich; 5’ 
CCGGCGTGATCTTCACCGACAAGATCTCGAGATCTTGTCGGTGAAGATCACGTTTTT 3’).  shRNA 
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plasmids were transformed in DH5α cells, grown up overnight at 37°C, then purified using Maxiprep kits 
(Qiagen).  DNA purity was checked with Nanodrop, and rejected if 260/280 or 230/260 values were below 
1.8.  Plasmids were then sequenced by the UNC genome sequencing facility.  Lentivirus was packaged 
by the UNC Lentiviral core, then aliquoted before use.  Neurons were seeded on plates for 24h before 
virus was added directly to media (MOI, > 1, DIV1).  4-5 shRNAs were pooled to achieve maximum 
knockdown.  On DIV18, H2O or ethanol (50 mM) was added directly to the media for 4hr then cells were 
harvested for membrane preparation and western blot analysis. 
 
siRNA Transfections.  Neurons were grown until DIV17 then transfected with 25 pmol Silencer® HDAC3 
siRNA (Cat# 4390771, Thermo Scientific) or Silencer® Select Negative Control No. 1 siRNA (Cat# 
4390843, Thermo Scientific) using Lipofectamine® RNAiMax Reagent (Thermo Scientific) following 
manufacturer’s instructions.  After 20hr, cells were exposed to 50 mM EtOH or H2O for 4hr, then 
harvested for membrane preparation and western blot analysis.  
 
Transfection for HDAC1-3 overexpression. HDAC1 overexpression plasmid was a gift from p181 pK7-
HDAC1 (GFP) was a gift from Ramesh Shivdasani (Addgene plasmid # 11054). HDAC2 overexpression 
plasmid was acquired from Origene (Cat# RR211585). pCMV5-Flag-HDAC3 was a gift from Qingbo Xu 
and Lingfang Zeng (Addgene plasmid # 63676).  Neurons were grown until DIV15, then transfected using 
FuGENE6 HD (Promega) following manufacturer’s instructions.  On DIV18, H2O or ethanol (50 mM) was 
added directly to the media for 4hr then cells were harvested for membrane preparation and western blot 
analysis. 
 
For additional methods on in vivo experiments, western blotting and qPCR, see Chapter 1 methods. 
 
Results 
 In order to test the hypothesis that ethanol exposure changes histone deacetylase expression we 
utilized the three expression paradigms previously introduced (Figure 6, Figure 12, and Figure 15) in 
order to determine if HDAC expression was modified due to pharmacological activation by ethanol, 
36 
recruitment from acute withdrawal, or due to physiological changes due to the development of 
dependence. 
 
Figure 21.  Chronic ethanol changes expression of Hdac2 and Hdac3.  qPCR analysis reveals that 
Hdac2 and Hdac3 are selectively upregulated after chronic ethanol exposure and withdrawal in the 
cortex.  n = 5-7.  * = p < 0.05, ** = p < 0.01, **** = p < 0.0001.  Significance was determined using two-
way ANOVA followed by Bonferroni post-hoc test.  All data are plotted as mean ± S.E.M. 
  
We analyzed expression of all 11 HDAC using qPCR in whole cortex lysates following chronic 
ethanol exposure and withdrawal.  Chronic ethanol exposure and 24hr withdrawal caused upregulated 
Hdac2 (1.27 ± 0.07 fold control) and Hdac3 (2.02 ± 0.13 fold control), which was prevented by the 
administration of TSA (Hdac2: 1.03 ± 0.10 fold control and Hdac3: 1.32 ± 0.18 fold control, p < 0.01).  A 
significant main effect of ethanol exposure was found for Hdac2 (F1,20 = 13.10, p = 0.0017, n = 7,7,5,5) 
while a significant interaction was found for Hdac3 and TSA (F1,18 = 6.233, p = 0.0225, n = 7,5,5,5) using 
two-way ANOVA.  We did not observe any changes in Hdac1, 4-11 after chronic ethanol exposure and 
withdrawal and/or TSA treatment. 
 Since HDACs signal in large complexes (e.g. HDAC2 = CoREST, NuRD, Sin3; HDAC3 = N-CoR-
SMRT)75 increased gene expression is not considered a very reliable functional readout for HDAC 
activity.  Thus, we evaluated HDAC1-3 expression to see if there was increased recruitment of Class I 
HDACs to the chromatin by preparing chromatin fractions. 
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Figure 22.  Chronic ethanol exposure and withdrawal recruits HDAC2 and HDAC3 to the 
chromatin.  A) Representative blots showing that there is increased HDAC2 and HDAC3 but not HDAC1 
in the chromatin fraction after chronic ethanol exposure and withdrawal.  B) Quantification of HDAC1 
expression.  C) Quantification of HDAC2 expression.  D) Quantification of HDAC3 expression.  n = 6.  ** = 
p < 0.01, *** = p < 0.001.  Significance was determined using Student’s unpaired two-tailed t-tests.  All 
data are plotted as mean ± S.E.M.   
 
 Chronic ethanol exposure increased HDAC2 and HDAC3 association with chromatin (HDAC2: 
135.4 ± 5.6% control, HDAC3: 178.9 ± 15.2% control).  However, the closely related HDAC1 did not show 
increased association with chromatin.  Next, we wanted to evaluate if these changes were initiated by 
exposure to ethanol or induced during a withdrawal period. 
 Previous studies have shown that histone deacetylase activity decreases while histone 
acetyltransferase activity increases after acute ethanol exposure80.  We wanted to evaluate if these 
changes were true in both the cortex and if these changes were due to changes in expression.  We again 
used one intoxicating dose of ethanol (Figure 15).  
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Figure 23.  Acute intoxicating dose of ethanol dose not change Hdac1-3 expression.  qPCR 
analysis reveals that there is no change in expression of Hdac1-3 in cortex after a single intoxicating dose 
of ethanol.  n = 5-6.  Statistical significance was determined using Student’s unpaired two-tailed t-test.  All 
data are plotted as mean ± S.E.M.  
 
 A single intoxicating dose, unlike chronic ethanol and withdrawal, did not cause a change in any 
of the HDAC transcripts measured (Figure 23).  Therefore, we wondered if there was any change in the 
recruitment of HDAC1-3 to the chromatin in the cortex after a single intoxicating dose of ethanol. 
 
 
Figure 24.  Acute ethanol intoxication does not recruit HDAC1-3 to chromatin.  A) Representative 
blots of HDAC1-3 in the chromatin fraction after chronic ethanol exposure.  B) Quantification of HDAC1-3.  
n = 7-9.  Significance was determined using Student’s unpaired two-tailed t-test.  All data are plotted as 
mean ± S.E.M. 
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 We did not observe any increases in HDAC1-3 after a single acute intoxicating dose of ethanol 
(Figure 24).  We next evaluated changes in HDAC1-3 expression after withdrawal in order to determine if 
acute withdrawal or chronic withdrawal was necessary for increased association with of HDAC2 and 
HDAC3 with the chromatin (Figure 22).  We hypothesized that changes in HDAC2 and HDAC3 
expression were likely only to occur after chronic ethanol exposure and withdrawal because this is the 
only time point that there were differences in GABAA-R subunit transcript expression (Figure 7 and 
Figure 13). 
 
 
Figure 25.  Acute withdrawal causes elevations of Hdac1 and Hdac2 transcript.  Acute intoxication 
followed by 24hr withdrawal caused an elevation in Hdac1 and Hdac2 transcript levels as measured by 
PCR.  There was no change in Hdac3 transcript.  n = 6.  Significance was determined using Student’s 
unpaired two-tail t-test.  * = p < 0.05, ** = p < 0.01.  All data are plotted as mean ± S.E.M. 
 
 Acute intoxication and 24hr withdrawal caused an increase in Hdac1 and Hdac2 transcript 
expression (Figure 25, Hdac1: 1.80 ± 0.31 fold control; Hdac2 1.83 ± 0.35 fold control).  Next we 
evaluated changes in HDAC1-3 associated with the chromatin. 
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Figure 26.  Acute withdrawal does not increase HDAC1-3 association with chromatin.  A) 
Representative blots showing that acute ethanol exposure followed by 24hr withdrawal does not increase 
HDAC1-3 association with chromatin.  B) Quantification of HDAC1-3 blots.  n = 6.  Significance was 
determined using Student’s unpaired two-tailed t-test.  All data are plotted as mean ± S.E.M. 
 
 We did not observe any statistically significant changes in HDAC1-3 expression after acute 
withdrawal (Figure 26).  Since we observed changes in Gabra1 and Gabra4 expression we were 
interested to determine if HDAC1-3 were associated with the promoter regions of these genes.  Since the 
previous studies only showed that there were global increases after chronic ethanol exposure and 
withdrawal, these studies would allow us to determine more functional relevance by determining if there 
was direct interaction.  This is measured using chromatin immunoprecipitation (ChIP) assays (Figure 27) 
using specific antibodies against HDAC1-3 and primers designed towards the promoter region of the 
GABAA-R gene.  The promoter region was selected due to previous ChIP sequencing studies that 
HDAC1-3 were preferentially associated with the promoter region of the gene as opposed to other 
regulatory elements or the gene body105.   
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Figure 27.  Schematic of chromatin immunoprecipitation assays.  Chromatin immunoprecipitation 
assays work by cross-linking regions of the genome associated with a histone post-translational marks or 
epigenetic regulators (in this case HDAC2) using formaldehyde, shearing DNA in tiny fragments, then 
using specific antibodies to pulldown the both the protein against the antibody and the cross-linked DNA 
fragment.  Following reversal of the cross-links (usually using heat), the relative amount of protein target 
of interest (in this case HDAC2) associated with the region of interest (in this case Gabra1 promoter) can 
be ascertained by comparing the pull-down to the input sample. 
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Figure 28.  Chronic ethanol exposure and withdrawal increase HDAC2 and HDAC3 association 
with the Gabra1 promoter.  A) Chronic ethanol exposure and withdrawal does not increase HDAC1 
association with the Gabra1 or Gabra4 promoter.  B) Chronic ethanol exposure and withdrawal increases 
HDAC2 association with the Gabra1 promoter but not the Gabra4 promoter and this is prevented by the 
administration of TSA.  C) Chronic ethanol exposure and withdrawal increases HDAC3 association with 
the Gabra1 promoter but not with the Gabra4 promoter.  n = 4-6.  Statistical significance was determined 
using two-way ANOVA followed by Bonferroni posthoc test.  *** = p < 0.001, **** = p < 0.0001.  All data 
are plotted as mean ± S.E.M. 
 
Chronic ethanol exposure and withdrawal does not increase HDAC1 association with the Gabra1, 
Gabra4, nor Gabrg2 promoter (Figure 28B).  Chronic ethanol exposure increases HDAC2 association 
with the Gabra1 promoter (0.25 ± 0.01% input) that was prevented by TSA (0.15 ± 0.01% input).  There 
was a significant interaction between ethanol and TSA exposure for HDAC2 associated with the Gabra1 
promoter (F1,16 = 7.353, p = 0.0154) using two-way ANOVA.  No statistically significant change was 
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observed for HDAC2 association with the Gabra4 or Gabrg2 promoter after chronic ethanol exposure or 
TSA administration (Figure 28B).  HDAC3 association with the Gabra1 promoter was also increased after 
chronic ethanol exposure (0.18 ± 0.02% input) and prevented by TSA (0.07 ± 0.03% input).  There was a 
significant interaction between ethanol and TSA exposure for HDAC3 associated with the Gabra1 
promoter (F1,20 = 46.05, p < 0.0001, n = 6) found using two-way ANOVA.  No statistically significant 
change was observed for HDAC3 association with the Gabra4 or Gabrg2 promoter after chronic ethanol 
exposure or TSA administration (Figure 28C). 
 Since we observed statistically significant increases in HDAC2 and HDAC3 association with the 
Gabra1 promoter we wanted to further evaluate the role of HDAC2 and HDAC3 in regulating Gabra1 and 
α1 expression.  In order to do this we utilized a cultured cortical neuron model.  Previous papers in the lab 
have demonstrated that exposure of cultured cortical neurons to 50 mM ethanol for 4h causes a decrease 
in α1 expression in the membrane fraction56,106.  These findings are also functionally relevant as there is 
decreased zolpidem potentiation after 4h of 50 mM ethanol exposure106.  However, we did not know if 
changes in Gabra1 expression occurred after 4h of 50 mM ethanol exposure.  In addition, it was unclear if 
both HDAC2 and HDAC3 were required for decreases in Gabra1 expression, or if either isoform was 
sufficient.  We first tested this methodology pharmacologically, by co-exposing neurons to 50mM ethanol 
and either broad or selective HDAC inhibitors and then analyzing Gabra1 expression. 
 
 
Figure 29. Hydroxamates and carboxamides prevent ethanol-induced decreases in Gabra1 
expression in cultured cortical neurons. Neurons exposed to hyxdroxamates for either 7 days or 4h 
prevent decreases in Gabra1 expression caused by 4hr of EtOH exposure.  The HDAC3 selective 
carboxamide prevents decreases ethanol-induced decreases in Gabra1 expression at 24nM and 80 nM.  
The class II selective hydroxylamine does not prevent ethanol-induced decreases in Gabra1 expression.  
Sodium butyrate, a different class of broad spectrum HDAC inhibitor also does not prevent the ethanol-
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induced decrease Gabra1 expression.  n = 3-6.  Statistical significance was determined using two-way 
ANOVAs followed by Bonferroni posthoc tests.  * = p < 0.05, ** = p < 0.01, *** = p < 0.001, and **** = p < 
0.0001.  All data are plotted as mean ± S.E.M. 
 
 Similar to results that were observed in the in vivo model of chronic ethanol exposure and 
withdrawal (Figure 7), TSA (500 nM) co-exposure prevented decreases in Gabra1 expression (1.27±0.06 
fold control) that was caused by 4h of 50 mM ethanol exposure (0.66±0.07 fold control).  There was a 
significant effect of TSA exposure on Gabra1 expression  (F1,20 = 23.21, p = 0.0001) as determined by 
two-way ANOVA.  Pre-exposure to TSA (500 nM) for 7 days increased Gabra1 expression (2.08±0.06 
fold control), which also prevented (1.17±0.19 fold control) a decrease caused by 4h of 50 mM ethanol 
exposure (0.71±0.16 fold control).  There was a significant effect of TSA exposure on Gabra1 expression 
(F1,8 = 22.51, p = 0.0015) as determined by two-way ANOVA.  Co-exposure to the FDA approved drug 
Vorinostat aka SAHA (3 µM) also prevented (1.24±0.13 fold control) the decrease caused by ethanol 
exposure (0.57±0.14 fold control).  There was a significant effect of SAHA exposure on Gabra1 
expression (F1,15 = 9.408, p = 0.0078) as determined by two-way ANOVA.  Co-exposure to HDAC3 
specific inhibitor107 RGFP966 at both 24nM and 80 nM (0.80±0.06 fold control, 1.20±0.17 fold control, 
respectively) prevents decreases in Gabra1 expression caused by ethanol exposure (0.39±0.06 fold 
control, 0.49±0.05 fold control, respectively).  There was a significant interaction between ethanol 
exposure and RGFP966 exposure on Gabra1 expression at both concentrations tested, (24 nM: F1,8 = 
26.47, p = 0.0009; 80 nM: F1,20 = 7.758, p = 0.0114) as determined by two-way ANOVA.  In contrast, 
exposure to the broad spectrum inhibitor sodium butyrate (1 mM) caused a decrease in Gabra1 
expression, even in the absence of ethanol (0.71±0.01 fold control).  Co-exposure with the class II HDAC 
inhibitor MC1568 (1 µM)  did not prevent (0.54±0.04 fold control) the decrease  in Gabra1 expression 
caused by ethanol (0.5±0.03 fold control).  There was a significant main effect of ethanol for MC1568 on 
Gabra1 expression (F1,20 = 64.49, p < 0.0001) as measured by two-way ANOVA (Figure 29). 
 Based on our results showing that 50 mM ethanol causes a decrease in Gabra1 expression that 
can be prevented by certain pharmacological agents and since our HDAC3 selective pharmacological 
agent prevented decreases in Gabra1 expression when co-exposed with ethanol, it suggested that 
inhibiting only HDAC2 or HDAC3 would be sufficient to prevent the decreases in Gabra1 expression, as 
well as provide insight if one isoform was more important than the other. 
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 In order to test the hypothesis that inhibiting only one HDAC isoform was sufficient to prevent the 
effects of ethanol on Gabra1 and α1 expression we utilized genetic tools in order to selectively target 
HDAC1, HDAC2, and HDAC3.  HDAC1 was chosen as a control due to it being closely related to HDAC2 
and HDAC3.  We utilized a lentiviral strategy for HDAC1 and HDAC2, while we were forced to utilize a 
siRNA strategy for HDAC3, as knockdown of HDAC3 proved to be lethal to neurons. 
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Figure 30.  Knockdown of HDAC1-3 prevents decreases in GABAA-R α1 subunit expression in 
cultured cortical neurons.  A) Schematic for lentiviral delivery of shRNA to knockdown HDAC1 and 
HDAC2 and ethanol exposure.  B) Schematic demonstrating siRNA transfection strategy to knockdown 
HDAC3 and ethanol exposure.  C) Quantification of HDAC1 knockdown.  D) Quantification of HDAC2 
knockdown.  E) Quantification of HDAC3 knockdown.  F) Quantification of α1 expression after HDAC1 
knockdown.  G) Quantification of α1 expression after HDAC2 knockdown.  H) Quantification of α1 
knockdown after HDAC3 knockdown.  I) Representative blots for HDAC1 knockdown and α1 expression.  
J) Representative blots of HDAC2 knockdown and α1 expression.  K) Representative blots for HDAC3 
knockdown and α1 expression.  n = 4-6.  Statistical significance was determined using two-way ANOVA 
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followed by Bonferroni post-hoc tests.  * = p < 0.05, ** = p < 0.01.  SC = scrambled control; SE = 
scrambled + ethanol exposure; KC = knockdown control; KE = knockdown + ethanol exposure.  Data are 
normalized to %scrambled control.  All data are plotted as mean ± S.E.M.  
 
 Lentiviral transduction of shRNAs targeted against HDAC1 produced knockdown of 58.78± 3.4% 
control.  Knockdown of HDAC1 prevented (118.00±8.23% control) the ethanol-induced decrease in α1 
expression (75.09±5.16% control).  There was a significant effect of HDAC1 knockdown on α1 expression 
(F1,19 = 19.32, p = 0.0003) determined by two-way ANOVA.  Lentiviral transductions of shRNAs targeted 
against HDAC2 produced knockdown of 63.08±7.09% control.  Knockdown of HDAC2 prevented 
(106.40±11.81% control values) the ethanol-induced decrease in α1 expression (60.02±9.15% control 
values).  There was a significant interaction of ethanol exposure and HDAC2 knockdown on α1 
expression (F1,17 =7.521, p = 0.0139) determined by two-way ANOVA.  Transfection of siRNA targeted 
against HDAC3 produced knockdown of HDAC3 to 64.79±4.34% control.  Knockdown of HDAC3 
prevented (101.9±4.91% control) the ethanol-induced decrease in α1 expression (78.64±2.49% control).  
There was a significant interaction between ethanol exposure and knockdown of HDAC3 on α1 
expression (F1,19 = 9.403, p = 0.0064) determined by two-way ANOVA. 
 Since chronic ethanol caused an increase in HDAC2 and HDAC3 associated with the chromatin 
fraction, we next wanted to see if by increasing expression without the presence of ethanol if this would 
decrease α1 expression.   
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Figure 31.  HDAC2 overexpression decreases α1 expression in cultured cortical neurons.  A) 
Schematic detailing transfection time point and ethanol exposure.  B) Quantification of α1 expression 
following HDAC1 overexpression and ethanol exposure.  C) Quantification of α1 expression following 
HDAC2 overexpression and ethanol exposure.  D) Quantification of α1 expression following HDAC3 
overexpression and ethanol exposure.  E) Representative blots of HDAC1 and α1 expression.  F) 
Representative blots of HDAC2 and α1 expression.  G) Representative blots of HDAC3 and α1 
expression.  MC = mock control, ME = mock ethanol, OC = overexpression control, OE = overexpression 
ethanol. ** = p < 0.01, n.s. = not significant. n = 4-6. Significance was determined by two-way ANOVA 
followed by Bonferroni post-hoc tests. Data are normalized to %mock control.  All data are plotted as 
mean ± S.E.M  
 
 HDAC1 expression did not cause a significant decrease in α1 expression (91.93±4.96% control).  
There was no significant effect of overexpression on α1 expression (F1,18 = 1.960,  p = 0.1785),  however 
there was a significant effect of ethanol exposure on α1 expression (F1,18 = 13.00, p = 0.002) determined 
by two-way ANOVA.  HDAC2 overexpression had a significant effect on α1 expression (59.89±5.36% 
control) which was similar to values observed when HDAC2 overexpressed in the presence of ethanol 
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(54.19±3.72% control).  There was not a significant interaction between HDAC2 overexpression and 
ethanol exposure on α1 expression (F1,15 = 1.063, p = 0.3188) but there was a significant effect of 
overexpression on α1 expression (F1,15 = 33.89, p < 0.0001) determined by two-way ANOVA.  HDAC3 
overexpression did not cause a significant decrease in α1 expression (99.84±6.36% control), there was 
no significant effect of overexpression on α1 expression (F1,20 = 0.1418, p = 0.7105) but there was a 
significant effect of ethanol exposure on α1 expression (F1,20 = 10.32, p = 0.0044) determined by two-way 
ANOVA. 
 
Conclusions 
 Chronic ethanol exposure and withdrawal upregulates Hdac2 and Hdac3 in cortex, similar to what 
was found in the VTA88.  This upregulation in transcript was not observed after acute intoxication, which 
was different from what was previously found in blood in humans and rodents84.  After acute withdrawal 
only Hdac1 and Hdac2 were upregulated and not Hdac3, this suggests that Hdac2 may be upregulated 
after acute withdrawal episodes, while Hdac3 is upregulated in response to multiple ethanol exposures 
and withdrawals.  However, while there is an increase in transcript, it was only after chronic ethanol 
exposure and withdrawal was there increased HDAC2 and HDAC3 association with the chromatin, 
suggesting that recruitment to the chromatin rely on repeated exposure and withdrawal episodes, and 
that there may be another level of ethanol-induced regulation of HDAC2/3. 
 After chronic ethanol exposure, there was an increase in HDAC2 and HDAC3 with the promoter 
region of the Gabra1 promoter.  This suggests that HDAC2 and HDAC3 are key molecular players in the 
chronic ethanol-induced regulation of the Gabra1 expression.  Further evidence for this was 
demonstrated that knockdown of HDAC2 and HDAC3, and selective pharmacological inhibition of HDAC3 
prevented decreases in Gabra1 expression and α1 expression.  However, knockdown of HDAC1 also 
prevented decreases in α1 expression.  One explanation for this is that HDAC1 and HDAC2 are often 
found together in repressive complexes (Sin3, NuRD, CoREST)105 and that knocking down HDAC1 
prevented proper functioning of these repressive complexes, perhaps by preventing these complexes 
from being recruited to the Gabra1 promoter by ethanol or by inhibiting the repressive ability of these 
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complexes, and that was what was preventing decreases in α1 expression.  Future experiments will have 
to address these possibilities.  Pharmacological evidence using MC1568 clearly implicated that class I 
HDACs, of which HDAC1-3 are part of, are essential for the ethanol-induced downregulation of α1 
expression, as blocking class II HDACs did not prevent decreases of ethanol-induced downregulation of 
α1.  The role of each of these HDACs was further clarified by overexpression experiments which clearly 
found that overexpression of only HDAC2 led to decreases in α1 expression.  An interesting observation 
was that none of these HDACs were upregulated after 4hr ethanol exposure in vitro, though Gabra1 
expression was clearly diminished.  This does not preclude the possibility that HDAC activity has 
increased or that there is increased association of HDAC1-3 with the Gabra1 promoter.  Future 
experiments will have to be conducted in order to validate this model system further. 
Large scale ChIP-seq studies have found that HDAC2 and HDAC3 are often associated with the 
promoter regions of genes that are actively being transcribed105.  This raises the question of whether 
repeated withdrawal episodes are recruiting these two HDAC isoforms in either an aberrant process 
induced by ethanol or this is a regulatory process to shut down GABAergic signaling due to potentiation 
by acute ethanol.  As the number of withdrawals increase there should be a corresponding increase in 
HDAC2 expression that can be modeled using a positive correlation.  The second possibility could be 
addressed by increasing GABAergic signaling, either using the native ligand GABA in culture or by 
increasing inhibitory signaling in the brain and then evaluating the natural mechanism for repressing 
Gabra1 expression.  These studies may inform better therapeutics as it will inform whether antagonizing 
GABAA during drinking (which has traditionally failed in clinical populations) or if correcting HDAC 
dysfunction using HDAC inhibitors is a more viable therapeutic approach.  There is some validity to the 
latter approach, as Ro 15-4513, an GABAA-R inverse agonist, has been suggested that it can prevent 
ethanol intoxication108 and drinking109.  
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CHAPTER 4:  Acetylation of the Gabra1 promoter as mechanism of ethanol control over α1 
expression
Introduction 
 Few studies have analyzed how ethanol decreases Gabra1 expression mechanistically.  Studies 
in epilepsy where there is decreased α1 expression suggest that changes occur through opposing PKA 
and PKC signaling cascades that terminate on activation of CREB and ICER respectively70.  In order for 
CREB to bind to DNA and initiate transcription, first it must be phosphorylated on serine 133, bind to its 
coactivator CREB binding protein (CBP)110, an acetyltransferase, which opens the chromatin structure 
and allows for sequence specific transcription factors to be recruited111.  This suggests that acetylation is 
necessary step to the regulation to the transcription of Gabra1, and therefore decreases in acetylation 
driven by increased association of histone deacetylases at the Gabra1 promoter may ultimately be the 
missing key to understanding ethanol’s ability to regulate the Gabra1 transcript thereby solving a long 
standing issue in the field.  
Acetylation is one of the best studied of all histone PTMs, and is well characterized in its role of 
permitting or activating gene transcription.  There are relatively few studies describing the role of 
acetylation in drug addiction in animal models.  Older studies have shown that chronic ethanol exposure 
induces a condensed chromatin state112, possibly implying a deacetylation mechanism. More recent 
studies have directly tested this hypothesis and found that following chronic ethanol consumption there is 
a decrease in both H3 and H4 acetylation and that this can be prevented by histone deacetylase 
inhibitors80,81.  No studies have evaluated the role of histone acetylation and GABAA-R subunit expression 
during chronic ethanol exposure.  What little evidence there is of histone PTM regulation of GABAA-Rs 
comes from one study evaluating the effects of cocaine.  This study showed that HDAC inhibitor MS-275 
prevents sensitization to the effects of cocaine and that injection of these inhibitors increases some 
GABAA subunit transcript expression in the nucleus accumbens102.  Important differences between the 
cocaine study and the alcohol study exist: first cocaine increased acetylation measured in the nucleus 
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accumbens, whereas as ethanol decreases acetylation in the VTA and amgydala.  This suggests that the 
drug of abuse and the brain region are important for changes in histone PTMs. The effects due to cocaine 
were largely due to HDAC1 involvement102 while most alcohol studies, including the studies described 
here (Figure 28 and Figure 31), indicate a role for HDAC288,99,101 or HDAC3.  We found no evidence in 
our molecular system that HDAC1 overexpression had significant changes on α1 subunit expression, 
where HDAC2 overexpression clearly showed a decrease in α1 expression (Figure 31). 
 One problem with this general hypothesis is that other histone PTMs are involved in gene 
regulation, and histone deacetylation may not be the only mark at play after chronic ethanol exposure.  
Indeed, in cocaine exposure there is an interplay between histone acetylation and histone methylation 
that works in tandem to regulate GABAA-R expression and cocaine-induced behavior102.  In the alcohol 
field, it has been shown that in humans, life-time alcohol consumption modifies gene transcription through 
H3K4me385,113, which is generally considered a permissive mark.  It has been observed that HDAC 
inhibitors can actually increase different histone methylation marks, causing transcriptional repression of 
histone demethylases114.  Exposure to ethanol in adolescence causes an increase in the repressive 
histone PTM, H3K9me2 when measured in adult rodents115.  Dependent animals have a decrease in the 
permissive mark H3K9me1 and knockdown of the histone methyltransferase PRDM2 increases drinking 
behavior116. Thus it is important in order to clarify which of these histone PTMs are most critical in order to 
better inform the development of therapeutics. 
 The development of CRISPR-Cas9 technology, which allows for highly selective targeting of 
regions of genomic DNA, allows for precise testing of this question.  CRISPR-Cas9 constructs designed 
by Dr. Charles Gersbach’s group at Duke University have attached the histone acetyltransferase domain 
of P300 to a catalytically inactive Cas9, which retains its ability to be targeted to specific DNA regions by 
sgRNAs, but loses its endonuclease ability93.  This allows us to directly test the hypothesis of whether or 
not acetylation is the driving histone PTMs behind changes in Gabra1 expression after ethanol exposure. 
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Figure 32.  Schematic of the dCas9-P300 system to probe acetylation sites.   When dCas9 attached 
to a P300 histone acetyltansferase domain is introduced into a cellular system with a sgRNA this 
facilitates binding a specific DNA loci (which are complementary to sgRNA (red lines) and a P300 domain 
that transfers acetylation to a histone.  This is hypothesized to increase gene transcription. 
  
Our in vivo model will be used to address several other questions: 1) does chronic ethanol exposure 
cause global changes in acetylation in the cortex; 2) are there changes in acetylation located at the 
Gabra1 promoter; 3) are there other epigenetic marks at play?  Clarification of these questions will lead to 
greater understanding of the histone PTMs that regulate Gabra1 expression and histone PTMs that occur 
after chronic ethanol exposure. 
Methods 
sgRNA production.  sgRNAs were designed in silico (crispr.mit.edu) based on experimentally 
determined algorithms described by Hsu et al, 2013117 to be targeted at the promoter region or exon 5 
and areas measured by ChIP primers.  BsmBI sites (fw = 5’ TCCC 3’; rev = 5’ AAAC 3’) were added to 
the CRISPR design in order to facilitate subcloning into the vector (FgH1tUTG was a gift from Marco 
Herold [Addgene plasmid # 70183])118.  Oligos were annealed in a thermocycler starting at 95°C and then 
decreasing by 5°C every minute until 20°C.  Oligos (100µM of both fw and rev) were then phosphorylated 
with T4 PNK ligase according to manufacturers instructions (NEB. Cat# M0201S).   Golden gate cloning 
was used to insert sgRNA oligos into FgH1tUTG (100 ng) by digesting with BsmbI (Fermentas, Cat# 
ER0451) and annealing with T7 ligase (NEB, Cat# M0318S) in thermocycler (37°C for 5 min then 23°C 
for 5 min, 15 cycles, hold at 4°C).  Reaction was then transformed into homemade Sbtl3 cells by following 
manufactuers instructions, (Zymo Research, Cat# T3001 made from Thermo Scientific, Cat# C737303), 
plated on LB-Amp plates 37°C and grown overnight.  Individual colonies were selected, grown overnight 
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in LB-Amp media at 37°C.  Plasmid DNA was extracted using Miniprep kits (Promega, Cat# A1340) then 
sequenced using the H1 primer.  For sgRNA sequences see Table 3.  Correctly sequenced clones where 
then packaged into lentivirus by the UNC Lentiviral Core. 
 
Subcloning dCas9-P300 into lentiviral expression vector.  We utilized a previously characterized 
dCas9-P300 construct93 for experiments.  dCas9-P300 construct was in a vector under the CMV reporter, 
which has poor expression in neurons119, therefore we subcloned the dCas9-P300 constructs (Addgene # 
61357 and 61358, a generous gift from Dr. Charles Gersbach) into a lentiviral expression vector with an 
RFP promoter (Addgene # 17619). dCas9-P300 was amplified out of the vector using the following 
primers designed with 20bp overhangs for Gibson assembly using PCR then extracted using PCR 
cleanup kits.  The lentiviral vector was cut using EcoRV (NEB, Cat# R0195S), fragment purified using 
Qiagen Gel Extract kit (Qiagen, Cat# 28704).  The two fragments were then using Gibson assembly 
following manufacturers instructions(NEB, Cat# E2611S).  Clones were sequenced by Eton Biosciences 
then packaged into lentivirus by the UNC Lentiviral Core. 
 
Lentiviral production of dCas9-VP64 and dCas9-KRAB. Plasmids containing dCas9-VP64 (Addgene # 
53192) and dCas9-KRAB (Addgene #71237) were a generous gift from Dr. Charles Gersbach.  dCas9-
VP64 was characterized previously by Kabadi et al, 2014120.  dCas9-KRAB was characterized previously 
by Thakore et al, 201594.  Plasmids were sequenced by Eton Biosciences then packaged into lentivirus by 
the UNC Lentiviral Core.  
 
Transduction of cortical neurons and ethanol exposure.  Equal volumes of three different lentiviruses 
with three different sgRNAs were mixed together with an equal volume of dCas9 vector (P300, 
P300D1399Y, VP64, or KRAB) and transduced into neurons DIV15 with 10 µg of polybrene (Sigma Aldrich, 
Cat# H9268).  On DIV16, doxycycline in H2O was added to cell culture medium (final concentration = 1 
µg/mL) in order to induce sgRNA expression118.  On DIV18, 50 mM EtOH or equivalent volume ddH2O 
was added for 4hr then cells were harvested for qPCR, ChIP or western blot analysis.   
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For in vivo dosing and methods, western blot, qPCR, ChIP, and culturing cortical neurons, see Chapter 2 
and Chapter 3 methods subsection. 
	
Results 
 Since previous studies have shown that chronic ethanol exposure causes a decrease in 
acetylation80,81, we wanted to verify that this occurred after chronic ethanol gavage and 24hr withdrawal in 
the cortex.  
 
 
Figure 33.  Chronic ethanol exposure causes global changes to histone acetylation which is 
prevented by TSA.  A)  Representative blots showing that chronic ethanol exposure and withdrawal 
causes a decrease in global H3 acetylation which can be prevented by the administration of TSA.  B) 
Quantification of global levels of H3 PTMs after chronic ethanol exposure.  n = 3-6.  ** = p < 0.01, **** = p 
< 0.0001.  Significance was determined by two-way ANOVA followed by Bonferroni posthoc tests.  All 
data are plotted as mean ± S.E.M. 
	
 Chronic ethanol exposure caused a 27.4±1.17% decrease in H3 acetylation as measured by a 
pan-acetylation antibody compared to H2O controls.  This was prevented by the administration of TSA 
(223.82±12.55% control).  TSA administration caused a 347±18.37% increase in H3 acetylation over 
control values.  There was a significant interaction between ethanol exposure and TSA administration on 
H3pAc expression (F1,20= 18.38, p = 0.0004) determined by two-way ANOVA.  Acetylation of histone 3 
lysine 9 (H3K9Ac) and histone lysine 14 (H3K14ac) are considered to be marks of permissive acetylation, 
and are commonly located at the promoter.  Chronic ethanol exposure caused a decrease in H3K9Ac 
(16.85±11.50 % control) which was prevented by the administration of TSA (103.61±19.86% control).  
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There was a significant interaction between ethanol exposure and TSA administration on H3K9Ac (F1,20 = 
8.212, p = 0.0096) determined by two-way ANOVA.  Chronic ethanol exposure also caused a decrease in 
H3K14Ac (12.64±5.13% control) that was prevented by the administration of TSA (92.31±22.32% 
control).  There was a significant effect of TSA administration on H3K14Ac (F1,18 = 4.069, p = 0.0589).  
Chronic ethanol exposure had no effect on H3K27Ac, nor any methylation mark that was measured, 
H3K4me2, H3K4me3, nor H3K9me3.  Since we observed global changes in H3pAc, we next wanted to 
know if these changes occurred at the Gabra1 promoter where we had previously observed changes in 
HDAC2 and HDAC3 association after chronic ethanol (Figure 22). 
 
	
Figure 34.  TSA prevents ethanol-induced decreases of acetylation associated with the Gabra1 
promoter and TSS.  Chronic ethanol exposure causes a decrease in the acetylation associated at both 
the promoter and the transcription start site (TSS) but not with distal exon 5 nor with Gabra4 or Gabrg2 
promoter.  n = 4-6.  * = p < 0.05, ** = p < 0.01, **** = p < 0.0001.  Significance was determined with two-
way ANOVA followed by Bonferroni posthoc test.  All data are plotted as mean ± S.E.M.  
 
 Chronic ethanol exposure caused a decrease in H3pAc associated with the Gabra1 promoter 
(29.54±7.16% control) that was prevented by the administration of TSA (147.45±27.66% control).  There 
was a significant effect of TSA administration (F1-16 = 8.840, p = 0.0090) as determined by two-way 
ANOVA.  Chronic ethanol exposure also caused a decrease of H3pAc associated with the Gabra1 TSS 
(27.31±7.08% control) which is prevented by the administration of TSA (128.32±9.43% control).  There 
was a significant effect of TSA administration on H3pAc associated with the Gabra1 TSS (F1,16 = 33.98, p 
< 0.0001) determined by two-way ANOVA.  There was no effect of ethanol exposure and/or TSA 
administration of the H3pAc associated with the fifth exon of the Gabra1 gene.  Similar to what was 
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observed with HDAC2 and HDAC3 association with Gabra4 promoter and Gabrg2 promoter, there was 
no effect of either ethanol and/or TSA on acetylation enrichment at these loci. 
 Since we observed changes in H3K9Ac but not H3K9me3 we wanted to see if this mark also 
specifically had decreased enrichment with the Gabra1 promoter.  We preformed ChIP assays with 
antibodies specific to these two H3 PTMs in order to determine if there was divergence at the Gabra1 
promoter compared to what was observed globally (Figure 33) and with the H3 pan-acetylation antibody 
(Figure 34).  
 
 
Figure 35.  Chronic ethanol exposure and withdrawal decreases H3K9Ac but not H3K9me3.  A) 
Chronic ethanol exposure and withdrawal causes a decrease in H3K9Ac associated with the Gabra1 
promoter and this is prevented by the administration of TSA.  B) Chronic ethanol exposure and 
withdrawal does not change H3K9me3 associated with the Gabra1 promoter.  n = 6.  * = p < 0.05, *** = p 
< 0.001.  Significance was determined by two-way ANOVA followed by Bonferroni posthoc test.  C = H2O 
gavage + Vehicle, E = EtOH gavage + Vehicle, T = H2O gavage + TSA, TE = EtOH gavage + TSA.  All 
data are plotted as mean ± S.E.M.  
 
 Chronic ethanol exposure causes a decrease in the H3K9Ac that was associated with the Gabra1 
promoter (7.30±0=4.51% control) and this was prevented by the administration of TSA (148.04±24.317% 
control).  There was a significant interaction between ethanol exposure and TSA administration on 
H3K9Ac associated with the Gabra1 promoter (F1, 20 = 8.647, p = 0.0081).  H3K9me3 is considered a 
repressive mark, thus we were interested to see if chronic ethanol increased H3K9me3 at the Gabra1 
promoter.  We did not observed changes in H3K9me3 after chronic ethanol (149.53±12.84% control) nor 
ethanol and TSA (41.23±13.40% control). 
 Although we did not observe any changes in GABAA-R subunit expression (Figure 16) nor 
HDAC1-3 expression (Figure 23) or association with the chromatin after acute ethanol (Figure 24), we 
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wanted to see if there were global changes induced after a single intoxication dose of ethanol in order to 
see if other HDACs or mechanisms may be involved in order to initiate changes in GABAA-R expression. 
 
 
Figure 36.  Acute ethanol intoxication does not alter H3 PTMs.  A) A single intoxicating dose (5g/kg) 
does not significantly change H3 PTMs.  B) Quantification of H3 PTMs after a single intoxicating dose.  n 
= 8-9.  Significance was determined using Student’s unpaired two-tailed t-tests.  All data are plotted as 
mean ± S.E.M. 
 
 Acute ethanol intoxication did not alter any of the H3 PTMs that were tested.  Next, we wanted to 
determine if there were changes in H3 marks after an acute withdrawal to determine if changes in H3 
marks observed after chronic ethanol exposure (Figure 33) were due to repeated withdrawal episodes or 
due to a single withdrawal episode. 
 
59 
 
Figure 37.  Acute withdrawal selectively decreases H3K14Ac in the cortex.  A) Representative blots 
showing that a single dose of ethanol (5g/kg, i.g.) followed by 24hr withdrawal causes a decrease in 
H3K14Ac but not in other H3 PTMs measured.  B) Quantification of different H3 PTMs after acute 
withdrawal.  n = 5-6.  * = p < 0.05.  Significance was determined using Student’s unpaired two-tailed t-
test.  All data are plotted as mean ± S.E.M.  
 
 Acute withdrawal caused a significant decrease in H3K14Ac (54.45±8.68% control) but did not 
significantly alter any other H3 PTMs measured.  We next wanted to test the hypothesis that acetylation 
at the promoter region was most likely the driving force behind decreased Gabra1 expression (Figure 7 
and Figure 29) in order to do that we turned to a CRISPR-Cas9 mediated strategy. 
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Figure 38.  CRISPR-Cas9 strategy for determining if ethanol regulates Gabra1 expression through 
a deacetylation mechanism.  A)  CRISPR-dCas9 constructs.  dCas9 fused to P300 is driven by EF1α 
promoter with a dsRed fluorescent protein being driven off a CMV promoter.  Inducible sgRNA expression 
is driven off an H1 promoter coupled to a Tet Off regulatory element that is inhibited by the addition of 
doxycycline, with a Ub promoter driving Tet repressor element and eGFP reporter.  B) Fluorescent 
microscopy image showing co-expression of eGFP (sgRNA construct, green) and dsRed (dCas9-P300 
construct, red) labeled with yellow arrows.  C)  Hypothetical schematic demonstrating dCas9-P300 to 
prevent decreases in acetylation associated with the Gabra1 promoter using sgRNAs.  D) Schematic 
demonstrating experimental design, lentiviral infections at DIV15, doxycycline added to the media at 
DIV16, EtOH exposure on DIV18 in cultured cortical neurons. 
 
 In order to test the hypothesis that ethanol was driving decrease in Gabra1 expression through a 
deacetylation mechanism we developed the following system: first, an inducible sgRNA in order to have 
precise control over when dCas9 is recruited to the Gabra1 promoter by modulating when sgRNA’s are 
synthesized; second, a fluorescent reporter on each construct in order to verify that both sgRNAs and 
dCas9 are co-transducing the same cells; third, dCas9 attached to P300 domain as described earlier 
(Figure 32) to allow for targeted acetylation at the Gabra1 promoter; finally, packaged into lentivirus so 
that system could be readily applied in vivo and for high efficiency for delivery of dCas9 and sgRNA 
plasmids.    
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Figure 39.  Targeted acetylation at the Gabra1 promoter prevents ethanol-induced decreases in α1 
expression.  A)  dCas9-P300 targeted to the Gabra1 promoter increases acetylation associated with the 
Gabra1 promoter.  B) Targeted acetylation of the Gabra1 promoter prevents decreases in Gabra1 
expression caused by ethanol.  C) Targeted acetylation of the Gabra1 promoter prevents decreases in α1 
expression.  n = 3.  * = p < 0.05.** = p < 0.01, *** = p < 0.001.  Significance was determined using two-
way ANOVAs followed by Bonferroni posthoc tests.  All data are plotted as mean ± S.E.M.   
 
 Directing the dCas9-P300 construct towards the Gabra1 promoter prevented the decrease 
(412.41±117.52% control) in H3pAc associated with the Gabra1 promoter caused by ethanol exposure 
(21.98±6.69% control).  There was a significant effect of targeting dCas9-P300 to the Gabra1 promoter on 
enrichment of H3 acetylation at the Gabra1 promoter (F1,8 = 22.10, p = 0.0015) determined by two-way 
ANOVA.  In addition, directing the dCas9-P300 construct towards the Gabra1 promoter prevented 
(5.60±1.04 fold control) the ethanol-induced decrease in Gabra1 transcript expression (0.22±0.03 fold 
control).  There was a significant effect of targeting dCas9-P300 to the Gabra1 promoter on Gabra1 
expression (F1,8 = 111.5, p < 0.001) determined by two-way ANOVA.  In addition, without the presence of 
ethanol, dCas9-P300 increases acetylation  at the Gabra1 promoter (349.84±64.28% control) and Gabra1 
expression (6.22±0.26 fold control).  We next evaluated if changes in transcript correlated with changes in 
membrane expression.  Targeting dCas9-P300 to the Gabra1 promoter prevented (96.69±6.03% control) 
the decrease caused by ethanol exposure (49.89±5.69% control).  There was a significant interaction 
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between targeting dCas9-P300 to the Gabra1 promoter and ethanol exposure on α1 expression (F1,8 = 
14.32, p = 0.0054).  We next wanted to evaluate whether or not the changes we observed on Gabra1 
expression was due to directing a dCas9 construct at this location or if this was due to an acetylation 
mechanism.   
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Figure 40.  Both acetyltransferase activity and targeting Gabra1 promoter are required to prevent ethanol-
induced changes in Gabra1 expression.  A) Using an inactive version of P300 with the aspartic acid at 1399 
mutated to a tyrosine does not prevent the ethanol-induced decrease in Gabra1 expression.  B) Targeting dCas9 to 
exon of the Gabra1 gene fails to prevent ethanol-induced decrease in Gabra1  expression.  C)  Using a dCas9 
construct that contains a VP64 activator domain instead of an acetyltransferase domain fails to prevent ethanol-
induced decreases in Gabra1 expression. n = 3. * = p < 0.05, **** = p < 0.0001.  Statistical significance was 
determined using two-way ANOVA followed by Bonferroni posthoc tests.  MC = mock transduced control, ME = mock 
transduced with ethanol exposure, PC = dCas9-P300 construct transduced with control exposure, PE = dCas9-P300 
construct transduced with ethanol exposure, VC = dCas9-VP64 transduced with H2O.  VE = dCas9-VP64 transduced 
with EtOH.  All data are plotted as mean ± S.E.M.    
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 We first tested whether histone acetyltransferase activity was necessary to prevent decreases in 
Gabra1 expression caused by chronic ethanol exposure.  To do this, we transduced neurons with a 
dCas9-P300 construct (dCas9-P300D1399Y) which was mutated at the D1399 residue to ablate 
acetyltransferase activity. We found that inhibiting acetyltransferase activity did not prevent decreases 
caused by ethanol (0.65±0.01 fold control) as there was a significant effect of ethanol exposure on 
Gabra1 expression (F1,8 = 91.08, p < 0.0001) determined by two-way ANOVA.  Next, we wanted to see if 
targeting anywhere in the Gabra1 gene would prevent ethanol-induced decreases in Gabra1 expression.  
We designed an sgRNA to target exon 5, where we previously did not observe any changes after any 
treatment in vivo (Figure 34).  Targeting exon 5 of the Gabra1 gene did not prevent ethanol-induced 
decreases of Gabra1 expression (0.37±0.01 fold control) as there was a significant effect of ethanol 
exposure on Gabra1 expression (F1,8= 415.0, p < 0.0001) determined by two-way ANOVA.  Finally, we 
wanted to see if this was acetylation based or activator based, because in some cases dCas9-P300 
targeting increases transcription under homeostatic conditions93.  We utilized a dCas9-P300 construct 
that had been fused with a VP64 transactivator domain and targeted it to the same location as the dCas9-
P300 from earlier experiments (Figure 39).  These constructs have previously been shown to activate 
gene transcription when targeted towards other genes and regulatory elements93,120.  Targeting the 
Gabra1 promoter with dCas9-VP64 failed to prevent decreases (53.71 ± 5.75% control) caused by 
ethanol exposure in α1 expression (70.39 ±5.61% control) and there was no increase in protein levels in 
the absence of ethanol exposure (104.5±5.61% control).  Analysis by two-way ANOVA revealed a 
significant effect of ethanol exposure on α1 expression (F1,8 = 12.61, p = 0.0082).  Since our data 
indicated that acetyltransferase activity at the Gabra1 promoter was necessary for changes in we wanted 
to see if we could block this effect using a different dCas9 construct attached to repressor domain, 
Krüppel-associated box repressor (dCas9-KRAB), that increases H3K9me394. 
 
 
 
65 
 
Figure 41.  Repressive dCas9-KRAB does not potentiate ethanol’s effect on α1 expression.  A) 
Schematic demonstrating hypothesize situation where ethanol deacetylation and dCas9-KRAB induced 
repressive H3K9me3 decrease Gabra1 expression.  B) α1 expression after ethanol exposure and dCas9-
KRAB targeting to the Gabra1 promoter.  C) Gabra1 promoter acetylation measured by ChIP assay after 
ethanol exposure and/or dCas9-KRAB targeting of the Gabra1 promoter.  D)  H3K9me3 associated with 
the Gabra1 promoter measured by ChIP assay after ethanol exposure and/or dCas9-KRAB targeting to 
the Gabra1 promoter.  n =3.  * = p < 0.05; ** = p < 0.01.  Significance was determined using two-way 
ANOVAs followed by Bonferroni post-hoc tests.  MC = mock control (H2O exposure), ME = mock and 
ethanol exposure (50 mM), KC = dCas9-KRAB transduction and H2O exposure, KE = dCas9-KRAB 
transduction and ethanol exposure (50 mM). All data are plotted as mean ± S.E.M.    
 
 Targeting the Gabra1 promoter with dCas9-KRAB did not potentiate (77.87±11.37% control) the 
effect of ethanol exposure (71.28±4.25% control) on α1 expression, although dCas9-KRAB without 
ethanol exposure also decreased α1 expression (71.20% ± 18.42% control).  There was no significant 
interaction between ethanol exposure and dCas9-KRAB targeting of the Gabra1 promoter (F1,8 = 2.212, p 
= 0.1753), although there was also no effect of ethanol exposure (F1`,8 = 0.8583, p = 0.3813) nor of 
dCas9-KRAB targeting of the Gabra1 promoter (F1,8 = 0.8718, p = 0.3378) on α1 expression as 
determined by two-way ANOVA.  This may be due to sample size, as the n is only 3.  Ethanol exposure 
did cause a decrease in Gabra1 promoter acetylation in the absence (41.44 ± 4.26% control) and 
presence of dCas9-KRAB (33.77±10.34% control).  dCas9-KRAB did not cause a decrease in Gabra1 
promoter acetylation in the absence of ethanol (81.46±10.94% control).  There was a significant effect of 
ethanol exposure on Gabra1 promoter acetylation (F1,8 = 21.05, p = 0.0018) determined by two-way 
ANOVA.  We next analyzed is there were changes in H3K9me3 associated with the Gabra1 promoter in 
order to validate that dCas9-KRAB was working in our hands and if there was an interplay between 
acetylation and H3K9me3.  Similar to what was observed previously, dCas9-KRAB increased H3K9me3 
in the presence (435.05±132.85% control) and absence of ethanol exposure (393.76±21.71% control).  
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Ethanol exposure did not increase H3K9me3 associated with the Gabra1 promoter (129.89±18.03% 
control).  Two-way ANOVA analysis revealed that there was no significant interaction between ethanol 
exposure and dCas9-KRAB being targeted to the Gabra1 promoter on H3K9me3 associated with the 
Gabra1 promoter (F1,8 = 0.006812, p = 0.9363) but there was a significant effect of targeting dCas9-KRAB 
to the Gabra1 promoter (F1,8 = 18.81, p = 0.0025).  
 
Conclusions 
 Chronic ethanol exposure leads to decreases in H3 acetylation associated with the Gabra1 
promoter and this is most likely the mechanism driving decreases in α1 expression.  Several converging 
lines of evidence support this, first, chronic ethanol exposure in vivo causes a decrease in α1 and Gabra1 
expression, and this is prevented by the HDAC inhibitor TSA which increases acetylation globally and at 
the Gabra1 promoter. H3K27Ac which is normally associated either with enhancer regions or with 
developmental programs was not found to be changed by chronic ethanol exposure121.  Second, there are 
no changes in α1 subunit or Gabra1 expression or total H3 acetylation after either an intoxicating dose of 
ethanol or an acute withdrawal period.  Third, in vitro, ethanol exposure that mimics a chronic ethanol 
exposure causes a decrease in acetylation associated with the Gabra1 promoter, and this can be 
prevented by selectively targeting acetylation to the Gabra1 promoter using a modified Cas9 construct.  
Fourth, deacetylation also takes precedence over other forms of activation, as targeting a transactivator 
domain (VP64) to the Gabra1 promoter failed to rescue ethanol-induced decreases in α1 membrane 
expression.  Furthermore, increasing the association of the repressive H3K9me3 mark with the Gabra1 
promoter using dCas9-KRAB did not further decrease α1 expression, even though dCas9-KRAB did 
repress α1 expression, demonstrating that it is a functional construct.  This solves one long-standing 
question in the field of how chronic ethanol exposure causes a decrease in Gabra1 transcript expression, 
showing that this is mediated largely by an acetylation mechanism.  
 Acute ethanol withdrawal caused a decrease in H3K14Ac, which is commonly associated with 
active promoters122, suggesting that there is a decrease in gene transcription.  However, we did not 
observe increases in HDAC1-3 with the chromatin fraction after acute ethanol withdrawal (Figure 26) 
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which leaves the question, what is driving this global decrease in H3K14Ac and whether this change is 
relevant to driving changes in GABAA-R expression or the development of alcohol dependence.   
 We did not observe changes in histone acetylation after an acute intoxicating dose, although 
others have reported that acute ethanol increases acetylation and histone acetyltransferase activity in the 
rat amygdala80, mouse hippocampus86, and in cultured hepatocytes123 suggesting that perhaps there is 
species, organ, and brain region specific regulation of different histone acetylation marks.  Another 
interesting observation is that acute ethanol causes a decrease in H3K27me3 when α1 receptors are 
made insensitive to ethanol in double mutant (S270H, L277A) knockin mice83.  These mice have different 
gene transcription profiles124 and behavioral responses to ethanol125,126, and when coupled with changes 
in H3K27me3, suggests that perhaps acute changes in GABAA-R signaling may drive changes to 
epigenetic marks that act as feedback mechanisms for GABAA-R expression.  Agreeing with this fact is 
the finding that by knocking out the α1 subunit there are large changes in transcription that occur in both 
α1 knockout lines127. 
 We observed that H3K9 acetylation appears to be a critical acetylation mark for controlling the 
Gabra1 promoter expression.  ChIP-seq studies have found that H3K9Ac is commonly associated with 
the promoter region of genes122 where it most likely plays a role in transcriptional initiation.  Our results 
showed there was a significant decrease in H3K9Ac associated with the Gabra1 promoter after chronic 
ethanol exposure.  We also found that there was a decrease in global H3K9Ac, which is similar to what 
others have found in the amgydala of rats and alcohol preferring inbred P-rats80,89,101.  However, others 
have found that CIE treatment in C57BL/6 mice caused an increase in H3K9Ac83 similar to what was 
found after acute injections of ethanol.  It should be noted that C57BL/6 mice, like the inbred P-rats, 
consume high levels of alcohol and that the common thread here may be that ethanol reverses the 
decreased H3K9Ac in these inbred alcohol preferring strains back to homeostatic levels.  Interestingly, 
when sensitivity to ethanol is diminished using an GABAA-R α1 mutant knockin mouse there are no 
changes in H3K9Ac and H3K14Ac83. 
We did not observe changes in certain histone methylation marks (H3K4me2, H3K4me3, 
H3K9me3) after chronic ethanol and did not observe changes in H3K9me3 associated with the Gabra1 
promoter after chronic ethanol.  This suggested to us that regulation was not occurring through decreases 
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in the activating H3K4me2 and H3K4me3 mark or increased repressive H3K9me3.  However, we showed 
that changes in acetylation were driving changes in Gabra1 expression and that this was due to changes 
in acetylation at the promoter region.  Recent advances in gene-targeting technology using CRISPR-
Cas9 and derivatives that allow for specific acetylation (dCas9-P300)93 made testing this hypothesis 
viable.  Our results demonstrate that in cultured cortical neurons that are exposed to ethanol that there is 
a decrease in Gabra1 expression and that this can be prevented by specifically targeting acetylation to 
the promoter region.  This is interesting as it correlates well with our pharmacological data that shows that 
global increases in acetylation by inhibiting HDACs can be used prevent ethanol-induced changes in 
GABAA-R expression.  Also, it demonstrates the use of CRISPR-Cas9 technology to selectively prevent 
changes in a specific gene locus which can be used to either determine the mechanism in which a drug of 
abuse (in this case ethanol) is causing changes in transcription.   
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CHAPTER 5: Conclusions 
Conclusions 
 Alcohol use disorders are chronically relapsing disorders with few available treatment options.  
This work describes a novel treatment strategy using histone deacetylase inhibitors in order to prevent 
the effects of chronic alcohol use on the GABAergic system, specifically downregulation of the highly 
prominent α1 subunit.  Histone deacetylase inhibitors are already FDA approved for the treatment of 
lymphoma (Vorinostat).  The studies described here and by other groups80-82,102 find that remodeling 
chromatin and the transcriptional landscape can be useful for the treatment for addiction.   
 Chronic ethanol exposure caused a decrease in both Gabra1 and α1 subunit expression which 
was prevented by the administration of the HDAC inhibitor TSA.  These changes were correlated with an 
increase in HDAC2 and HDAC3 association with the chromatin and the Gabra1 promoter.  Increased 
HDAC2 and HDAC3 association with both the chromatin and the Gabra1 promoter led to a decrease in 
H3 acetylation.  Specifically, H3K9Ac, which is often found at the promoter region and is thought to be 
either permissive or involved in active transcription122 was decreased both globally and at the Gabra1 
promoter.  Early studies have suggested that TSA treatment only regulates approximately 5-10% of the 
genome105,128, which corroborates with our in vitro and in vivo results suggesting that the therapeutic 
value of TSA is only viable when there is aberrant gene expression occurring, as TSA treatment did not 
increase global levels of H3K9Ac nor H3K9Ac associated with the Gabra1 promoter.  Interestingly, we did 
not observe changes in H3K9Ac until after repeated ethanol exposure and 24h withdrawal, suggesting 
that recruitment of both HDAC2 and HDAC3 by ethanol is required for decreases in H3K9Ac both by 
globally and at the Gabra1 promoter.  Corroborating this fact is that after acute ethanol exposure and 
acute withdrawal there was no change in HDAC2 and HDAC3 associated with the chromatin and no 
change in global H3K9Ac.  Interestingly, we did observe a change in H3K14Ac.  H3K14Ac and H3K9Ac 
are often found together at the same locus but the majority is H3K9Ac122, which suggests that perhaps 
decreases in H3K14Ac after a single withdrawal are priming for future changes that occur after multiple
70 
 withdrawals.  Exploring this possibility further could begin to identify players that initiate dependence, 
which could be of great interest for therapeutic intervention.  
 HDACs are divided into four different classes. We used a broad spectrum HDAC inhibitor from 
the hydroximate class, TSA, to inhibit all HDACs (except Class III, the Sirtuins) in vivo.  Further 
pharmacological characterization in vitro demonstrated that broad-spectrum hydroximates and HDAC3 
selective inhibitors (RGFP966) were useful in preventing changes to Gabra1 expression suggesting that 
HDAC3 may be involved in decreasing Gabra1 expression after chronic ethanol exposure.  HDAC3 is the 
most highly expressed in the brain of the Class I HDACs129 and is important in normal development of the 
cortex130.  Further evidence for this was that HDAC3 was upregulated after chronic ethanol exposure in 
vivo and had increased association with the Gabra1 promoter.  Knockdown studies in vitro found that 
selectively targeting HDAC3 prevented decreases in α1 expression.  However, HDAC3 overexpression 
did not cause downregulation of α1 expression.  One experimental issue is that HDAC3 overexpression is 
known to be neurotoxic; this was not directly tested in our cultures131.  Another possibility is that HDAC3 
inhibition is sufficient to prevent decreases in α1 expression by ethanol but increased HDAC3 expression 
does not necessarily induce α1 expression.  One line of evidence that supports this reasoning is the 
observation that HDAC2 exhibited increased expression in the cortex and has increased association with 
the Gabra1 promoter after chronic ethanol exposure.  Several other studies have found that HDAC2 may 
be a critical modulator of ethanol’s action on gene transcription as it is more abundant in inbred alcohol 
preferring P-rats101, upregulated in human neuronal cell line SK-N-MC after ethanol exposure132, and 
upregulated in the mouse VTA after chronic ethanol exposure88.  Interestingly, HDAC2 and HDAC3 are in 
the same class of HDACs, but are not usually found in the same repressive complexes133 suggesting that 
there might be two distinct pathways that are being effected by ethanol.  Implicating HDAC2 in the 
regulation of Gabra1 is that HDAC2 overexpression directly decreases α1 expression and this is not 
potentiated further by ethanol.  Furthermore, specific knockdown of HDAC2 prevents the decrease in α1 
expression.  These results suggest that HDAC2 is a likely candidate for further therapeutic development.  
Interestingly, HDAC2 overexpression decreases memory formation and negatively effects synaptic 
plasticity104, both of which are signs of chronic ethanol consumption134.  
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 There is GABAA hypofunction in the cortex135 and decreased binding of certain benzodiazepine 
ligands in the brain of human alcoholics136-139, but there is either unchanged or elevated muscimol 
binding138,140 suggesting that there may be adaptations in receptor sub-types but not necessarily receptor 
number. Cross-tolerance to benzodiazepines65,141 is modeled in rodents, and this is associated with an 
increase in the α4 receptor and a decrease in the α1 receptor.  Changes in the receptors lead to clinically 
relevant changes in behavior, including increased anxiety via upregulation of the α4 subunit142,143 and 
decreased sensitivity to zolpidem due to downregulation of the α1 subunit.  We found that chronic ethanol 
exposure caused an open-field endophenotype, and that this could be prevented by the administration of 
TSA and potentially due to TSA administration decreasing α4 expression. Future studies will need to 
address whether there TSA can prevent anxiety-like behavior that is both reliant on GABAA-R expression 
and not reliant on locomotor activity, since our gavage paradigm caused a decrease in the amount of 
locomotor activity during withdrawal.  Additionally, TSA administration prevents cross-tolerance to 
zolpidem, suggesting that TSA administration can restore functional α1 receptors.  Finally, we found that 
TSA administration prevented a decrease in ethanol consumption in a two bottle choice paradigm.  
Combined, these results suggest that TSA administration restores normal GABAA expression and function 
in ethanol-dependent animals and this may contribute to decreased drinking. 
 We found an increase in Gabra4 and α4 subunit expression after ethanol exposure in agreement 
with previous studies47,49,62,65,144.  Interestingly, TSA prevented ethanol-induced upregulation of the α4 
subunit and the Gabra4 transcript.  Some reports have suggested that TSA can cause a down regulation 
of certain genes105,128, going against the canonical dogma that acetylation leads to increased gene 
transcription.  We wanted to test if this change was mediated through either an HDAC or acetylation 
mechanism.  However, we did not observe any changes in HDAC1-3 binding with the Gabra4 promoter, 
nor any change in acetylation at the Gabra4 promoter suggesting that changes in Gabra4 expression by 
ethanol and modulation by TSA are likely to occur through a different mechanism.  Egr3 stimulation 
upregulates Gabra4 expression in epilepsy145 and the same study found that PKC activation increases α4 
expression in hippocampal culture.  Certain PKC isoforms are upregulated after chronic ethanol 
consumption146 and PKC is known to regulate α4 GABAAR surface expression and GABAAR 
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function54,95,147,148.  This suggests that there may be an interaction between PKC and HDACs which could 
play an ultimate role in Gabra4 expression.  Future studies will have to address this possibility. 
 CRISPR-Cas9 technology has allowed for increased access to understanding epigenetic 
mechanisms by allowing for precise targeting of loci.  Our studies in vivo demonstrated that there was a 
decrease in acetylation associated with the Gabra1 promoter, however we were unsure if this was a 
byproduct of a different signaling cascade as acetylation marks are relatively transient122.  By utilizing a 
dCas9 attached to histone acetyltransferase we were able to demonstrate that selectively increasing 
acetylation at the Gabra1 promoter prevents ethanol-induced decreases in Gabra1 expression.  Several 
lines of evidence support this conclusion, first targeting the dCas9-P300 construct to a locus that did not 
appear to have ethanol-induced regulation of acetylation after chronic ethanol in vivo did not prevent 
ethanol-induced decreases in Gabra1 expression.  Second, utilizing a construct that did not have 
acetyltransferase activity showed that this was not merely offtarget effects from dCas9 being targeted to 
the promoter.  Further supporting this point is that a dCas9 construct attached to a transactivator domain 
(VP64) failed to prevent decreases in α1 expression.  Deacetylation also appears to be the major 
regulator of the Gabra1 promoter, as dCas9-KRAB which increases repressive H3K9me3 at the Gabra1 
promoter did not further decrease α1 expression in the presence of ethanol.  This suggests that 
deacetylation of the Gabra1 promoter by ethanol is most likely the driving force behind decreases in 
Gabra1 expression and that this can be prevented by either genetically diminishing or using 
pharmacological inhibition, or more selectively targeting this locus to increase acetylation using CRISPR-
dCas9. 
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Figure 42.  Final model of epigenetic control of the α1 subunit by ethanol and potential 
intervention nodes. Chronic ethanol exposure causes an increase in HDAC2 and HDAC3 which 
associated with the Gabra1 promoter, causing decrease in acetylation, and a downregulation of both 
Gabra1 transcript and α1 expression leading to dependence symptoms. Pharmacological, genetic, and 
epigenetic intervention can be used to prevent this effect from happening.   
 
 In conclusion, this thesis demonstrates that decreased Gabra1 expression is driven by decreases 
in acetylation at the Gabra1 promoter.  Deacetylation at the Gabra1 promoter is facilitated by HDAC2 and 
HDAC3 which are upregulated by chronic ethanol exposure and recruited to the Gabra1 promoter.  This 
can be blocked by pharmacological administration or by genetically depleting HDAC2 or HDAC3.  More 
targeted approaches can prevent deacetylation of the promoter by the use of CRISPR-dCas9-P300 
technology.  This may inform the development of new therapeutics for the treatment of dependence 
symptoms in human patients suffering from alcohol use disorders. 
Future directions 
 This thesis largely focused on changes to HDACs but did not address changes to other 
epigenetic components required to repress gene transcription, or recruit HDACs to the Gabra1 promoter.  
Future work will need to determine if there is divergence between HDAC2- vs. HDAC3-induced regulation 
of the Gabra1 promoter.  Furthermore, the class III HDACs, the sirtuins, were not formally tested.  The 
sirtuins are known to be involved in other addictive diseases149, and future work is needed to determine if 
they are involved in alcohol dependence mechanisms.   
 
 The use of CRISPR-dCas9 technology has shown that epigenetic modifications can restore 
transcriptional changes that occur after ethanol exposure, however, it is not know if restoring these 
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changes at such a specific loci will have any functional or behavioral effects.  Future experiments should 
evaluate these changes in vivo to conclusively demonstrate that specific loci and histone PTMs 
associated with these loci have behavioral and therapeutic relevance. 
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APPENDIX 
Table 1. Antibodies Antibodies used in studies, including manufacturer and catalogue number. 
Name Manufacturer Cat # 
GABAA-α1 Millipore AB5592-200 
GABAA-α4 Abcam Ab73874 
GABAA-β2 Novus NB300-198 
GABAA-β3 Novus NBP1-47613 
GABAA-δ Novus NB3002-200 
GABAA-γ2 Novus NB300-190 
β-Actin Novus NB600-501 
Anti-Acetyl-Histone H3 
(pan) 
Millipore #06-599 
H3 K9Acetyl Cell Signaling #C5B11 
H3 K14Acetyl Cell Signaling #7627 
H3 K27Acetyl Cell Signaling #4353 
H3 K4me2 Abcam ab7766 
H3 K4me3 Cell Signaling #9727 
H3 K9me3 Abcam ab8898 
Histone 3 Cell Signaling #3638 
HDAC1 Abcam ab7028 
HDAC2 Abcam ab7029 
HDAC3 Santa Cruz sc-11417 
GAPDH Abcam ab8245 
Anti-Flag™ Sigma Aldrich F7425 
 
 
Table 2 Primers Primers used in above studies for both chromatin immunoprecipitation assays and qPCR. 
ID 5’ -> 3’ 
ChIP Primers  
Gabra1 Prom Fw CCCCCAAAATAGAGGAATGC 
Gabra1 Prom Rv AATAGGCGGTGACTTCATGC 
Gabra1 TSS Fw GGACAAGCCCGTGATGAAGA 
Gabra1 TSS Rv TCCCGAGAGAGTGCTCAGAA 
Gabra1 Exon 5 Fw TGCCCAATAAACTCCTGCGT 
Gabra1 Exon 5 Rv CTGCAGGAATCATGGTTGTCC 
Gabra4 Prom Fw CCAAGGACTGTGGGTAGCAT 
Gabra4 Prom Rv GCTCAGCTCCGTACCTTGTC 
Gabrg2 Prom Fw TGAGCTGACGCTTTGATGGT 
Gabrg2 Prom Rv TCCCGTCACTCAGGAGATGT 
TaqMan Gene Expression Assays (Cat# 4453320, Applied Biosciences) 
Gabra1 Rn00788315_m1 
Gabra4 Rn00589846_m1 
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Gabrb2 Rn00564149_m1 
Gabrb3 Rn00567029_m1 
Gabrd Rn01517017_g1 
Gabrg2 Rn00788325_m1 
Hdac1 Rn01519308_g1 
Hdac2 Rn01193634_g1 
Hdac3 Rn00584926_m1 
Hdac4 Rn01427040_m1 
Hdac5 Rn01464245_m1 
Hdac6 Rn01528280_g1 
Hdac7 Rn01533232_m1 
Hdac8 Rn01419048_m1 
Hdac9 Rn01499096_m1  
Hdac10 Rn01407364_g1 
Hdac11 Rn01420983_m1 
Gapdh Rn01775763_g1 
 
Table 3 sgRNA sequences sgRNA sequences used to guide CRISPR-Cas9 with native PAM sequence. 
ID Sequence 5 -> ’3 PAM 
Gabra1 Promoter #1 TAATACGTCCCAGCGCAAAC CGG 
Gabra1 Promoter #2 ATTTCACATCCGGTTTGCGC TGG 
Gabra1 Promoter #3 TTTCACATCCGGTTTGCGCT GGG 
Gabra1 Exon 5 #1 TAATACGTCCCAGCGCAAAC CGG 
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